I. Introduction {#s2}
===============

Acute and chronic pain afflict millions of people each year at enormous cost in both health care and lost productivity ([@B96]). The high prevalence of pain is a major cause of health care utilization ([@B246]), and prescription and over-the-counter analgesics are among the most widely consumed drugs in the United States ([@B138]; <https://www.chpa.org/SalesVolume.aspx>). *μ* opioid receptor agonists in particular (e.g., morphine, hydrocodone, oxycodone, fentanyl, and methadone) are widely prescribed for treatment of relatively severe acute and chronic pain, although use of these drugs is limited by side effects that include abuse liability and potentially lethal respiratory depression ([@B209]). Overall, the prevalence of pain, demand for effective analgesics, and constraints on the use of existing drugs have driven a decades-long search for improved pain treatments, and the current crisis of opioid analgesic abuse and overdose deaths in the United States has invigorated this effort with new urgency ([@B270]). Preclinical-to-clinical translational research from laboratory animals to humans has played a key role in analgesic drug development in the past and will likely continue to be important in the future as lessons from previous failures and successes are integrated into evolving research strategies ([@B185]; [@B289]). This review will consider preclinical research strategies for candidate analgesic testing with a particular focus on behavioral outcome measures used to assess pain and the role of those outcome measures in the interpretation of drug effects.

Any preclinical procedure that aspires to pain measurement involves two components: 1) an experimental manipulation delivered to a research subject with the intent of producing a pain state (the principal independent variable, referred to below as the "pain stimulus"), and 2) the measurement of some change in behavior by that subject and interpreted as evidence of the pain state (the principal dependent variable, referred to below as the "pain behavior") ([@B185]; [@B269]; [@B160]; [@B40]; [@B279]). Once a model of "pain stimulus→pain behavior" has been established, then drugs can be evaluated for their effectiveness to reduce the pain behavior. For example, in a prototypical preclinical pain assay, delivery of a noxious heat stimulus to the tail of a mouse or rat can elicit a tail-withdrawal response. In this case, heat serves as the pain stimulus, the tail-withdrawal response serves as the pain behavior, and opioid analgesics such as morphine decrease that pain behavior. Parameters of the pain stimulus can be varied by altering its intensity, modality, or the anatomic site(s) to which it is applied, and clinical relevance can be further enhanced by incorporating treatments that produce inflammation, neuropathy, or other elements of pain-related injury or disease. Previous reviews have summarized advances in types of pain stimuli used to model clinically relevant pain states ([@B104]; [@B160]; [@B124]; [@B116]; [@B167]), and those different approaches are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Taxonomy of pain stimuli and associated examples

  Pain Stimulus                                                                 Definition                                                      Examples
  ----------------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------
  Acute noxious stimulus                                                        Able to produce tissue damage                                   Thermal-radiant heat
                                                                                                                                                Mechanical-pressure
                                                                                                                                                Chemical-acid
  Inflammatory ± evocative acute stimulus[*^a^*](#t1n1){ref-type="table-fn"}    Activates or mimics local or systemic inflammatory  processes   CFA Carrageenan
                                                                                                                                                Surgical Incision
  Neuropathic ± evocative acute stimulus[*^a^*](#t1n1){ref-type="table-fn"}     Damages peripheral sensory neurons or central neurons           Nerve ligation or constriction
                                                                                                                                                Chemotherapy
  Disease state ± evocative acute stimulus[*^a^*](#t1n1){ref-type="table-fn"}   Diabetes (e.g., streptozocin treatment)                         
                                                                                Bone cancer (e.g., cancer cell injection to bone marrow)        
                                                                                Migraine (e.g., glycerol trinitrate injection)                  
                                                                                Natural disease (e.g., arthritis in companion animals)          

Models of inflammatory, neuropathic, or disease-state pain often involve two stimuli: one to produce a relatively sustained state of inflammation, neuropathy, or disease-like pathology, and a second acute stimulus. The second stimulus is usually thermal or mechanical in modality and may range from innocuous to noxious in intensity. In subjects with inflammation/neuropathy/disease, the second acute stimulus may elicit pain behavior suggestive of "allodynia" (pain response to a normally innocuous stimulus) or "hyperalgesia" (hyperactive response to a normally noxious stimulus).

Pain stimuli can produce a variety of changes in behavior, and a central challenge to analgesic drug discovery is the selection of outcome measures appropriate for study. Pain has been defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage" ([@B97]). As such, pain is first and foremost a subjective experience that may be vivid and consuming to the subject in its grip; however, this subjective experience cannot be measured directly or objectively by an external observer. Instead, pain is expressed through the medium of behavior, and the detection of "pain," either in the clinic or the laboratory, is accomplished indirectly by assessment of behavior. Clinical pain assessment in verbally competent adults focuses largely on verbal behavior structured by instruments such as numeric rating scales or questionnaires ([@B56]; [@B154]). In subjects that lack verbal competence (e.g., young children or laboratory animals), verbal behavior is not available as a source of dependent measures, and pain diagnosis relies instead on changes in other, nonverbal behaviors ([@B185]; [@B271]; [@B24]; [@B132]; [@B152]). This review will describe a taxonomy of nonverbal pain behaviors and discuss basic principles of behavioral analysis that govern their expression and pharmacological modulation in preclinical and translational research. The classes of behaviors to be described are summarized in [Table 2](#T2){ref-type="table"}.

###### 

Taxonomy of pain behaviors and associated examples

  Type of Behavior                                 Notation                                                                Preclinical Examples                                                   Clinical Correlates
  ------------------------------------------------ ----------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------
  Unconditioned behavior: US→UR                    PS→UR                                                                   Stimulation of withdrawal responses,  writhing, flinching, grimacing   Same
  PS→\[US→UR\]                                     Depression of locomotion, feeding, wheel  running, burrowing, nesting   Impaired physical functioning                                          
  Classically conditioned behavior: CS+US; CS→CR   PS+CS; CS→CR                                                            Conditioned place avoidance; fear  conditioning                        Avoidance, anxiety, fear
  PS → \[US+CS; CS→CR\]                            Conditioned place preference to putative  analgesic treatments          Placebo analgesia                                                      
  Operant behavior: S^D^→R→S^C^                    PS→R→S^C^                                                               Discrimination of a noxious stimulus                                   Verbal reports of pain intensity or  quality
  S^D^→R→PS                                        Punishment with a noxious stimulus                                      Movement-induced pain                                                  
  PS→\[S^D^→R→S^C^\]                               Depression of operant responding for food  or brain stimulation         Impaired physical functioning                                          

The transduction of a pain stimulus into pain behavior is governed by both the evolutionary history (phylogeny) and the individual history (ontogeny) of the subject to which the stimulus is delivered. With regard to evolutionary history, the ability to detect and respond adaptively to noxious stimuli is fundamental to the survival of any organism, and natural selection operating over millennia has equipped members of any given species with genetic endowments that underlie anatomic traits and behavioral reflexes. Reflexive "unconditioned" pain behaviors have historically played a major role in preclinical pain research, and rodent tail-withdrawal responses from noxious heat exemplify this type of behavior. Reflexive behaviors are supplemented by customized stimulus-response relationships learned by individual organisms in the course of their own lifetimes via classical and operant conditioning. Conditioning enables individual organisms to learn new stimulus-response relationships tailored to the specific environments they inhabit, and conditioned behaviors are both prominent in pain expression by humans and increasingly important as outcome measures in preclinical pain research.

The remainder of this review will discuss basic principles of unconditioned, classically conditioned, and operant conditioned behaviors as they apply to preclinical research on the expression of pain and the pharmacology of candidate analgesics. Specific examples will be provided, strengths and weaknesses of each approach will be discussed, and opportunities for new research will be presented. Additionally, basic principles of pain behavior apply to both laboratory animals and humans, and the implications of these principles for translational research will be considered. In particular, a major rationale for preclinical pain research is the prioritization of candidate analgesics for advancement to clinical testing. To serve this purpose, translational research evolves in an iterative cycle of forward and back translation to select for strategies that promote sensitivity to and selectivity for drugs that function as analgesics in humans ([Fig. 1](#F1){ref-type="fig"}).

![Translational research involves an iterative process of forward and back translation to use and refine procedures that optimize sensitivity and selectivity for analgesic drugs. (A) A theoretical array of drugs that will ultimately function in humans as effective analgesics (filled circles) or as ineffective analgesics (open circles). The challenge in preclinical research is to identify the effective analgesics and filter out the ineffective compounds. Sensitive assays (green bracket) detect all or most true-positive analgesics but are vulnerable to false-positive effects with drugs that are not analgesics. Selective assays (red bracket) detect some or most true-positive analgesics and are less vulnerable to false positives with nonanalgesics; however, selective assays may yield false-negative results that fail to detect some analgesics. (B) A strategy to sequence assays with complementary characteristics of sensitivity and selectivity and prioritize candidate analgesics for human testing. An initial screen with a sensitive assay can identify a subset of drugs that includes both many true-positive analgesics but also some false positives. Additionally, these assays can be used to characterize attributes of in vivo pharmacology, including potency, efficacy, time course, and receptor mechanism(s) of action. Secondary testing with a selective assay can then screen out many false positives to identify high-priority drugs for advancement to human testing. Drugs effective in the sensitive assay but not in the selective assay may still have potential as analgesics (i.e., they may be false negatives in the selective assay), but such drugs would have lower priority for advancement. Drugs that are not effective in the sensitive assay can be rejected. (C) The iterative process of forward and back translation for use and refinement of preclinical procedures. In forward translation, candidate analgesics are prioritized for advancement to clinical studies. In back translation, drugs identified as effective or ineffective analgesics can be tested as positive or negative controls, respectively, and can also be used to refine preclinical procedures in ways that increase sensitivity to the positive controls and selectivity against negative controls.](pr.118.017210f1){#F1}

II. Behavioral Outcome Measures in Analgesic Drug Discovery {#s3}
===========================================================

A. Unconditioned Behavior {#s4}
-------------------------

### 1. Definition {#s5}

An unconditioned response is any stimulus-induced physiologic or behavioral response that does not require learning for its expression ([@B76]; [@B211]). Unconditioned responses are elicited by unconditioned stimuli, and the relationship can be described using the following terms:where US denotes the unconditioned stimulus and UR denotes the unconditioned response. Unconditioned responses are often mediated by relatively simple neural circuits that include a sensory component (to detect the US) coupled to a motor component (to activate muscles associated with the UR), and genetic foundations for the development of these circuits have been selected during evolution to enable rapid expression of adaptive responses to stimuli that are both common in the environment where a species has evolved and physiologically relevant to individual members of that species. Most unconditioned responses do not involve pain stimuli. For example, food presentation in the mouth can serve as a US to elicit the UR of salivation, and increased ambient light can serve as a US to elicit the UR of pupillary contraction. However, a subset of unconditioned responses is elicited by "noxious stimuli," which can be defined as "stimuli that damage or threaten to damage normal tissues" ([@B97]). Noxious stimuli are typically thermal (e.g., heat), mechanical (e.g., pressure), or chemical (e.g., protons) in modality, and they are detected by specialized sensory receptors ("nociceptors") embedded in the damaged or threatened tissue ([@B235]; [@B286]). Moreover, as with other US→UR relationships, unconditioned responses to noxious stimuli require some threshold level of stimulus intensity to elicit their expression, and increases in stimulus intensity above the threshold usually increase the rate, frequency, or intensity of the unconditioned response.

Unconditioned responses to noxious stimuli can be generally grouped into three different categories. First, noxious stimuli may elicit responses in physiologic subsystems within an organism without necessarily changing overt behavior. For example, a noxious heat stimulus may trigger action potentials in a subset of primary nociceptors, alter heart rate, or produce changes in patterns of cerebral blood flow ([@B7]; [@B152]; [@B219]). Second, noxious stimuli may elicit withdrawal responses that have the effect of removing the affected tissue away from the stimulus ([@B24]). The heat-induced tail-withdrawal response described above illustrates this type of response, and it can be described as "behavior" insofar as it involves coordinated movement of skeletal musculature in a way that can be readily detected and measured by an observer. Lastly, noxious stimuli may elicit other types of motor behavior that can be reliably evoked, observed, and measured, although they may not result in withdrawal from the stimulus ([@B24]). Examples here include abdominal writhing/stretching behavior, facial grimacing, or vocalization produced by an inescapable stimulus such as intraplantar or intraperitoneal administration of a chemical irritant.

### 2. Pain Stimulus as an Unconditioned Stimulus {#s6}

Measurement of the first category of unconditioned responses (i.e., physiologic responses) typically falls within the purview of physiologic research and will not be considered further here. The latter two categories, however, involve overt behaviors that can be readily detected by an external observer. For the purposes of this review, unconditioned behaviors elicited by noxious stimuli will be described using the following terms:where PS denotes the noxious "pain stimulus" and UR denotes the unconditioned response that serves as the primary outcome measure of pain-related behavior. These unconditioned behaviors have formed the foundation of preclinical research on pain and analgesic drug development for decades, and procedures to assess these behaviors have appeal for many reasons. Most importantly, these procedures possess a degree of face validity in relation to human behavior. For example, many of the unconditioned behaviors observed in laboratory animals (e.g., withdrawal from noxious heat) can also be observed in humans coincident with reports of pain ([@B125]; [@B161]), and some drugs (e.g., *μ* opioid receptor agonists) that decrease unconditioned pain-related behaviors in laboratory animals also decrease the sensation of pain in humans ([@B214]).

In addition to advantages associated with face validity, these procedures are also associated with technical advantages that facilitate their use in research. For example, many pain-related unconditioned behaviors occur at low levels in the absence of noxious stimulation, they can be reliably elicited by presentation of a noxious stimulus to untrained or minimally trained experimental subjects, and they can be modified by drugs to permit pharmacological assessment of drug attributes such as potency, efficacy, time course, and receptor mechanism ([@B279]). A final noteworthy advantage is that stimulus-response relationships can be sensitized by manipulations that produce inflammation or neuropathy ([@B185]). Sensitized stimulus-response relationships provide evidence for "allodynia" (nociceptive response to a normally innocuous stimulus) or "hyperalgesia" (heightened nociceptive response to a normally noxious stimulus) ([@B97]), which are often interpreted as evidence for inflammatory or neuropathic pain. For example, both intraplantar injection of complete Freund's adjuvant (CFA; to produce paw inflammation) or injury to the sciatic nerve (to model neuropathy in sensory neurons that innervate the paw) result in hypersensitive paw withdrawal in response to mechanical stimulation ([@B23]; [@B248]).

If these procedures were sufficient for accurate translational research on the expression, mechanisms, and treatment of pain, then this review would not be necessary. They are not sufficient, and recent failures in analgesic drug development have exposed key weaknesses ([@B200]; [@B89]; [@B90]; [@B65]; [@B289]). In considering these weaknesses, it is perhaps best to begin with a point of logic. Although a noxious stimulus may elicit both an unconditioned response and the sensation of pain in humans, it does not follow that the unconditioned response = pain, or that reducing the unconditioned response = a reduction in pain. This type of distinction between unconditioned responses and perceptual experiences is obvious in other stimulus modalities. In vision, for example, a dark theater may be suddenly illuminated by the opening scene of *Star Wars* (<https://www.youtube.com/watch?v=yHfLyMAHrQE>). Light from the screen will cause both an unconditioned response of pupillary constriction and a perceptual response of the words "Star Wars" outlined in yellow and receding against a star-filled night sky. These different responses, although caused by a common stimulus, differ in their underlying mechanisms and in their responses to drugs. For example, topical application of a muscarinic acetylcholine receptor antagonist like tropicamide might block pupillary constriction without affecting accuracy of perception, whereas a serotonin 2A receptor agonist hallucinogen like psilocybin might alter perception while having little effect on pupillary constriction.

In support of this distinction for nociception, a footnote to the definition of "pain" promulgated by the [@B97] points out that unconditioned "activity induced in the nociceptor and nociceptive pathways by a noxious stimulus is not pain, which is always a psychological state." It could be added that unconditioned behavioral responses to a noxious stimulus are also "not pain," and this distinction implies that mechanisms and modulators of pain in humans may differ from mechanisms and modulators of the unconditioned physiologic and behavioral responses to noxious stimuli commonly used as outcome measures in preclinical pain research. One of the most prominent examples of this distinction lies in the vulnerability of conventional preclinical procedures to treatments that produce motor impairment and behavioral depression. Specifically, common pain-related unconditioned behaviors (e.g., withdrawal reflexes) are "pain-stimulated behaviors," which can be defined as behaviors that increase in rate, frequency, or intensity after delivery of a noxious stimulus. These behaviors can be reduced by treatments that decrease sensory sensitivity to the noxious stimulus (true analgesia); however, these behaviors can also be reduced by treatments that impair the subject's motoric ability to emit the unconditioned response (e.g., by causing sedation or paralysis, or by increasing a competing behavior). Treatments that produce nonselective motor impairment often produce false-positive analgesic-like effects in conventional assays of pain-stimulated behavior.

[Figure 2](#F2){ref-type="fig"} illustrates the potential for misleading results from a preclinical study of drug effects on unconditioned pain-stimulated behavior ([@B16]). In this procedure, intraperitoneal administration of dilute acid (referred to here as "intraperitoneal acid") to mice served as an acute visceral noxious stimulus (the PS) to evoke an unconditioned response ("stretching" or "writhing," the UR). This UR was reduced by the clinically effective *μ* opioid analgesic drug morphine; however, stretching was also dose-dependently reduced by the centrally acting and pharmacologically selective *κ* opioid receptor agonist 2-(3,4-dichlorophenyl)-N-methyl-N-\[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl\]acetamide (U50,488). U50,488 has not been tested in humans, but other centrally acting *κ* agonists performed poorly in clinical trials, and *κ* agonists are not approved for pain treatment anywhere in the world ([@B200]; [@B123]).

![Assays of pain-depressed behavior can dissociate analgesics from drugs that produce motor impairment. (A and B) Effects produced in mice by the *μ* opioid receptor agonist (morphine) and a *κ* opioid receptor agonist (U50,488 or U69,593) in assays of pain-stimulated unconditioned behavior (A; intraperitoneal acid-stimulated stretching) or pain-depressed unconditioned behavior (B; intraperitoneal acid-induced depression of nesting). Abscissae show the dose in milligrams per kilogram. Ordinates are the number of acid-stimulated stretches (A) or zones cleared (B; a measure of nesting). Points above "V" indicate effects of vehicle administration. Filled points indicate significant differences from V (*P* \< 0.05). Both morphine and the *κ* agonist blocked acid-stimulated stretching, whereas only morphine was effective to block acid-induced depression of nesting. These results are consistent with clinical analgesic effectiveness of centrally acting *μ* but not *κ* agonists. IP, intraperitoneal; V, vehicle. Data adapted from [@B16] and [@B183].](pr.118.017210f2){#F2}

Accordingly, the apparent antinociceptive effect of U50,488 in the assay of intraperitoneal acid-stimulated stretching represents a false-positive effect with regard to preclinical-to-clinical forward translation, and this type of false positive has motivated efforts to refine preclinical testing procedures and improve predictive validity. The most common strategy to address this issue has been to compare drug potency in assays of unconditioned pain-stimulated behavior with drug potency in assays of motor performance, such as performance on a rotarod apparatus. The reasoning is that a given drug is more likely to function as an analgesic in humans if it produces preclinical antinociception at doses that do not produce signs of motor impairment in other behavioral procedures. However, relative potency to produce antinociception versus motor impairment has not proven to be a reliable predictor of analgesic potential. For example, one study found that both *μ* and *κ* opioid agonists had similar potency ratios for antinociception versus motor impairment on a rotarod task ([@B229]), but only *μ* agonists are approved as analgesics.

Two other points warrant mention with regard to the translational utility of conventional preclinical assays of pain-stimulated behavior. First, although both humans and nonhumans exhibit withdrawal reflexes from noxious stimuli, analgesic drugs are rarely used to block these withdrawal reflexes in humans. For example, medical procedures (e.g., surgery) are perhaps the most common context within which humans are treated with drugs to reduce pain-stimulated behaviors evoked by noxious stimuli (e.g., skin incision with a scalpel blade); however, drugs used in this context are usually local or general anesthetics (i.e., drugs that block all sensory modalities in the affected tissue) rather than analgesics (drugs that selectively reduce nociception without affecting other sensory modalities) ([@B280]). Second, the use of pain-stimulated unconditioned behaviors to assess allodynia and hyperalgesia in the context of inflammation and neuropathy is also problematic. Similar evocative stimuli are often used to assess allodynia and/or hyperalgesia in both laboratory animals and in humans (e.g., von Frey filaments to assess mechanical sensitivity; [@B37]; [@B117]); however, the behavioral outcome measures in laboratory animals and humans are dramatically different. Specifically, the terms "allodynia" and "hyperalgesia" refer to hypersensitivity of pain-stimulated unconditioned behaviors (e.g., paw withdrawal) in laboratory animals, but to hypersensitivity of verbal pain endorsement in humans, often in the absence of an accompanying withdrawal reflex. Thus, just as pain-stimulated unconditioned behaviors are not equivalent to the human experience or report of pain, preclinical measures of allodynia and hyperalgesia are not equivalent to clinical measures of allodynia and hyperalgesia in humans.

In summary, measures of pain-stimulated unconditioned behavior in laboratory animals are not equivalent to core outcome measures of pain in humans, they do not serve as reliable surrogate measures of pain, and treatment-induced decreases in pain-stimulated unconditioned behavior do not provide reliable evidence of analgesia. With regard to assay characteristics of sensitivity and selectivity ([Fig. 1](#F1){ref-type="fig"}), assays of pain-stimulated behavior are sensitive but not selective.

### 3. Pain Stimulus as a Contextual Stimulus {#s7}

In addition to stimulating unconditioned behaviors, noxious stimuli can also be part of the context in which other US→UR relationships are expressed. This relationship can be expressed as follows:where PS again denotes the noxious pain stimulus, US indicates a non-noxious unconditioned stimulus, and UR indicates the unconditioned response elicited by the US. In cases in which the pain stimulus is a contextual stimulus, expression of the unconditioned response is often depressed, and "pain-depressed behaviors" can be defined as behaviors that decrease in rate, frequency, or intensity after presentation of a noxious stimulus ([@B180]; [@B179]). For example, presentation of nesting material (the US) elicits nesting behavior (the UR) in many strains of mice under normal laboratory conditions, and noxious stimuli such as intraperitoneal acid can then serve as a contextual pain stimulus to depress nesting ([@B75]; [@B101]; [@B183]; [@B130]; [@B195]). Many other examples of pain-depressed unconditioned behavior have been reported, including depression by noxious stimuli of feeding (elicited by presentation of palatable food) ([@B249]; [@B120]), locomotor activity (elicited by a novel environment) ([@B148]; [@B250]), burrowing (elicited by presentation of a cylinder filled with a substrate such as gravel) ([@B5]; [@B226]; [@B283]; [@B233]), and wheel running (elicited by access to a running wheel) ([@B157]; [@B251]; [@B41]; [@B106]).

There are at least two potential benefits to incorporating assays of pain-depressed behavior into preclinical research on pain and analgesic drug development. The first is face validity. Behavioral depression (also known by other names such as "functional impairment" or "reduced activities of daily living") is a core outcome measure of pain in human and veterinary medicine, and alleviation of pain-depressed behavior is often a primary goal of treatment. For example, a set of core outcome measures has been recommended for use in human clinical trials of candidate analgesics by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials ([@B56]). The primary type of pain measure recommended by this group was verbal report of pain intensity and quality (to be discussed in section II.C.2), but the secondary recommendation was for measures of pain-depressed behavior assessed using instruments such as the Brief Pain Inventory or McGill Pain Questionnaire. The Parents' Postoperative Pain Measure is an especially instructive instrument for comparison with preclinical research approaches because it is intended for use with young children who may lack verbal competency, and it relies not on self-reports by the subject but on assessment of overt behavior by an external observer (in this case, the parents) ([@B36], [@B35]; [@B271]). The short form of the Parents' Postoperative Pain Measure evaluates 10 endpoints, five of which reflect behavioral depression (e.g., "Play less than usual"), whereas the other five reflect pain-stimulated behaviors (e.g., "Whine or complain more than usual"). Notably, in a study of the instrument's validity in postsurgical patients, parents endorsed more signs of pain-depressed than pain-stimulated behavior in their children ([@B271]). Assessment of pain-depressed behaviors also plays a major role in veterinary pain diagnosis. For example, a canine Brief Pain Inventory asks dog owners to rate pain-depressed behaviors in their pets ([@B31]). As another example, federal guidance on pain assessment in laboratory animals focuses on measures of depressed feeding and associated weight loss, depressed locomotor activity, and depressed grooming ([@B172]). The focus on pain-depressed behaviors in clinical pain diagnosis, especially when verbal reports are unavailable, suggests that measures of pain-depressed behaviors might also be a valuable source of endpoints in preclinical research.

A second advantage of pain-depressed behavior as an experimental endpoint is that drugs producing motor impairment do not produce false-positive analgesic-like effects. This results in increased assay selectivity. Specifically, in assays of pain-depressed behavior, the noxious stimulus itself decreases the behavioral endpoint, and analgesic drugs attenuate this behavioral depression to increase the target behavior. By contrast, drugs that produce motor impairment only exacerbate pain-related behavioral depression. For example, [Fig. 2](#F2){ref-type="fig"} shows effects of morphine and the centrally acting *κ* agonist *N*-methyl-2-phenyl-*N*-\[(5*R*,7*S*,8*S*)-7-(pyrrolidin-1-yl)-1-oxaspiro\[4.5\]dec-8yl\]acetamide (U69,593) on intraperitoneal acid-induced depression of nesting in mice ([@B183]). As noted above, intraperitoneal acid administration can serve as an acute visceral noxious stimulus that depresses nesting behavior. Morphine dose-dependently blocked intraperitoneal acid-induced depression of nesting, consistent with its known effectiveness as an analgesic; however, in this assay of pain-depressed behavior, the *κ* agonist failed to produce a morphine-like effect. The failure of U69,593 to alleviate acid-induced depression of nesting is consistent with the lack of clinical evidence for analgesic effectiveness and safety of centrally acting *κ* agonists ([@B200]; [@B123]).

In addition to these strengths, assays of pain-depressed behavior also present challenges. Most important among these is identification of conditions that generate high, stable rates of baseline behavior and reliable depression of that behavior by a noxious stimulus of interest. For example, a consortium of European investigators at eight different industry and academic research sites recently evaluated the reliability with which intraplantar CFA reduced burrowing behavior by rats ([@B283]). The study concluded that both baseline burrowing behavior and intraplantar CFA-induced depression of burrowing were generally reproducible across sites; however, the study also revealed within- and between-site variability in both baseline and intraplantar CFA-depressed behavior and began to identify factors (e.g., rat weight, time after intraplantar CFA administration, size of the burrowing substrate) that might influence behavioral outcomes. Other studies have found that putative inflammatory-, neuropathic-, and disease-related pain manipulations produce either little evidence for behavioral depression or a shorter duration of pain-depressed than pain-stimulated behaviors ([@B262]; [@B41]; [@B78]; [@B72]; [@B194]; [@B232]). For example, treatment of mice with the chemotherapy drug paclitaxel was sufficient to produce hypersensitive paw withdrawal in response to mechanical stimuli, a pain-stimulated behavior commonly interpreted as evidence of neuropathic pain; however, this paclitaxel treatment regimen was not sufficient to depress nesting behavior ([@B259]). Taken together, these results suggest that many preclinical models of inflammatory-, neuropathic-, and disease-related pain fail to produce a full spectrum of pain-related behaviors in laboratory animals and may not be adequate for research on treatments for dimensions of pain that involve behavioral depression and functional impairment.

A second challenge in assays of pain-depressed unconditioned behavior is that these baseline behaviors can be depressed by innocuous as well as noxious stimuli. As a result, demonstration that a given stimulus depresses behavior cannot be interpreted as evidence of pain, and interpretation of depressed behavior as "pain-related" requires other supporting evidence. For example, one study investigated the effects of noxious and innocuous stimuli on consumption of a palatable food in rats. In this study, rats reliably consumed a large number of food pellets under baseline conditions, and this consumption could be reduced either by a noxious stimulus (intraperitoneal acid) or by an innocuous stimulus (prefeeding to induce satiety) ([@B120]). Notably, the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen blocked depression of feeding by intraperitoneal acid but not by prefeeding. The sensitivity to a clinically effective analgesic supported the conclusion that intraperitoneal acid-induced depression of feeding was pain related, whereas prefeeding-induced depression of feeding was not.

As a third issue, assays of pain-related behavioral depression are theoretically vulnerable to treatments that produce nonselective behavioral stimulation. Thus, just as pain-stimulated behaviors may be reduced by treatments that produce false-positive motor impairment, pain-depressed behaviors might be restored by treatments that produce false-positive motor activation. This issue can be addressed experimentally by comparing effects of a given treatment on behavior depressed by a noxious stimulus with effects of that same treatment on behavior depressed by a non-noxious stimulus. For example, as noted above, the NSAID ketoprofen blocked intraperitoneal acid-induced depression of feeding in rats, but it did not block prefeeding-induced depression of feeding, and it also did not alter baseline feeding in the absence of a depressant stimulus ([@B120]). In this case, the selectivity of ketoprofen to block depression of feeding by a putative noxious stimulus supported the conclusion that ketoprofen effects resulted from true analgesia and not from general motor activation. This issue can also be addressed experimentally by comparing effects of test drugs with effects of stimulants like amphetamine. For example, intraplantar CFA administration reduced both horizontal and vertical (rearing) locomotor activity in rats ([@B148]). The NSAID ibuprofen alleviated both effects, whereas amphetamine alleviated CFA-induced depression of horizontal but not vertical locomotion. The authors concluded that vertical locomotion was less vulnerable than horizontal locomotion to general stimulant effects, and accordingly, they focused on vertical locomotion as the primary endpoint in evaluating other drugs.

A related theoretical point also warrants mention regarding the relative vulnerability of pain-related behaviors to nonselective motor impairment or activation. On the one hand, it is possible for a treatment to produce nonselective depression of all behavior; an extreme example is the elimination of all behavior by paralysis or death. On the other hand, it is less possible for a treatment to produce nonselective behavioral stimulation. An organism can engage in only a subset of behaviors at a time, and although periods of inactivity might be followed by expression of new behaviors, at some point, activation of any one behavior necessarily competes with and reduces expression of other behaviors. Thus, a treatment that increases some behaviors may not increase other behaviors (e.g., stimulation of a horizontal but not vertical locomotor activity by amphetamine in the example above) and may in fact decrease expression of other behaviors. For this reason, false-positive effects are more likely to be produced by nonselective motor impairment in assays of pain-stimulated behavior than by nonselective motor stimulation in assays of pain-depressed behavior.

A final weakness of assays of pain-depressed behavior is that they may fail to detect analgesic effects of drugs that also produce general disruption of behavior. As one example, it was noted above that intraplantar CFA reduced rearing in rats ([@B148]). This CFA-induced depression of vertical activity could be blocked by an intermediate morphine dose (1.0 mg/kg) but not by a higher dose (3.0 mg/kg) that robustly decreased rearing in the absence of the acid noxious stimulus. These results were interpreted to suggest that sedative effects obscured detection of antinociception at high morphine doses. More generally, morphine and other *μ* agonists usually produce antinociception at subsedative dose in assays of pain-depressed behavior (although not always; [@B77]). However, the sensitivity of these assays will be low for true analgesics that produce motor disruption at doses equal to or less than doses that produce analgesia.

### 4. Summary {#s8}

Noxious stimuli produce both pain-stimulated unconditioned behaviors and depression of other unconditioned behaviors, and both types of changes in behavior can serve as outcome measures in preclinical research on the mechanisms and treatment of pain. For example, intraperitoneal acid both stimulates a stretching/writhing response and depresses other unconditioned behaviors such as feeding, locomotion, and nesting in mice. Complementary use of assays that measure both classes of behavior can improve translational pain research, because clinical pain states involve both classes of behavior, and treatments that block sensitivity to the noxious stimulus should block both types of behavior. Moreover, coordinated use of these approaches can improve preclinical-to-clinical translation of drug effects as described in [Fig. 1](#F1){ref-type="fig"}, because assays of pain-stimulated and pain-depressed behavior have relatively high sensitivity and selectivity, respectively.

B. Classical Conditioning {#s9}
-------------------------

### 1. Definition {#s10}

Classical conditioning is a type of learning in which one stimulus (the conditioned stimulus, CS) gains effectiveness to produce a behavioral response (the conditioned response, CR) after being paired with an unconditioned stimulus ([@B67]; [@B211]). This learned relationship between stimuli leading to new responses can be diagrammed as follows:The CS is typically a stimulus that initially elicits little behavioral response, whereas the US elicits an unconditioned response as described above in section II.A (US→UR). Classical conditioning proceeds in two phases. First, during conditioning, the CS and US are presented together in a regimen of paired stimulus presentations (CS+US). Second, during testing, the CS is presented alone, and behavioral effects of the CS are evaluated. If conditioning has occurred, then the CS will elicit a CR (CS→CR). The prototypical example of classical conditioning is the "Pavlov's Dog" experiment, in which the CS was a ringing bell, the US was food presentation, and the UR was salivation; after repeated pairing of the ringing bell with food, the sound of the bell alone came to elicit the CR of salivation ([@B206]). In general, conditioned responses have the adaptive function of preparing the subject for the US, and CRs may be similar to or different from the UR. In the case of the "Pavlov's Dog" experiment, the ringing bell CS elicited a salivation CR in anticipation of food delivery.

The determinants of classical conditioning have been a topic of intense study for decades, and numerous basic principles have been identified ([@B67]; [@B211]). Two will be mentioned here. First, the effectiveness of a regimen of CS+US conditioning is influenced in part by the temporal relationship of CS and US presentation ([Fig. 3](#F3){ref-type="fig"}). In general, conditioning is most effective when the CS begins before and continues during presentation of the US (delay conditioning). Conditioning is less effective or ineffective when the CS is terminated before onset of the US (trace conditioning), delivered with an onset and offset identical to the US (simultaneous conditioning), or delivered after US onset (backward conditioning). Indeed, in backward conditioning, the CS may become associated with termination of the US rather than with its delivery. Second, conditioning is most effective when both the CS and US are reliably presented together. For example, conditioning is strongest when both the CS and US are novel at the outset of conditioning and are always presented together, whereas conditioning is weaker if the subject has had prior exposure either to the CS without the US (latent inhibition) or to the US without the CS (US pre-exposure effect). Moreover, an established CS→CR relationship can be weakened by repeated subsequent presentations of the CS without the US (extinction).

![Possible temporal alignments of a conditioned stimulus (CS) and unconditioned stimulus (US) in classical conditioning. Classical conditioning is most effective with "delay conditioning."](pr.118.017210f3){#F3}

In a second basic principle of classical conditioning, different experimental designs can be used to examine effects of drugs or other manipulations on either the development or the expression of a conditioned response. In studies to evaluate treatment effects on the *development* of a CR, the treatment is administered during the conditioning phase of the study (for example, as a pretreatment to each iteration of CS+US pairings). Under this type of design, treatments can modify the ultimate expression of the CR on the test day by modifying either 1) sensitivity to the CS or the US or 2) memory consolidation processes responsible for the association of the CS and US. By contrast, in studies to evaluate treatment effects on the *expression* of the CR, the treatment is administered only during the test phase, after the conditioning phase has been completed. Treatments can modify CR expression by modifying 1) sensitivity to the CS, 2) memory recall processes that link the CS to the CR, or 3) motor competence to perform the CR.

### 2. Pain Stimulus as the Unconditioned Stimulus {#s11}

In one type of classical conditioning design used in preclinical pain research, noxious "pain" stimuli play the role of the US. This role can be expressed as follows, with PS again denoting the pain stimulus:In this type of experiment, the PS is presented only during development of the CR in the conditioning phase, and as a result, candidate analgesic drugs are also administered during the conditioning phase to assess drug effectiveness to block development of the CR. One example of this approach is "conditioned place aversion" (CPA) ([@B102]; [@B256]; [@B52]; [@B265]; [@B275]; [@B16]), and [Fig. 4](#F4){ref-type="fig"} shows data from an example of a CPA study using a noxious stimulus as the US ([@B16]). Place-conditioning studies typically use an apparatus with at least two compartments (i.e., two "places") distinguished by different visual, tactile, and/or olfactory stimuli and separated by a removable barrier. For the study shown in [Fig. 4](#F4){ref-type="fig"}, the compartments had different wall colors and floor textures (black walls with a floor of parallel bars vs. white walls with a mesh floor). During conditioning, the barrier between compartments was in place, and one group of mice was treated with a noxious stimulus (intraperitoneal acid at a concentration sufficient to elicit stretching as a UR) prior to confinement for 40 minutes in one compartment, and with intraperitoneal saline prior to confinement for 40 minutes in the other compartment. Both types of conditioning session were conducted on the same day at least 4 hours apart, and the particular compartment paired with intraperitoneal acid was counterbalanced across mice. Thus, the distinguishing visual and tactile stimuli of the acid-paired compartment served as the CS, and the intraperitoneal acid injection served as the PS. A control group of mice was treated with vehicle in both compartments. Testing occurred 1 day later by placing mice back into the apparatus with the barrier removed so that mice could move freely between the two compartments for 15 minutes. Mice conditioned with intraperitoneal acid spent less time in the acid-paired compartment after conditioning than during a preconditioning trial, and this decrease in time spent in the acid-paired compartment is indicated in [Fig. 4](#F4){ref-type="fig"} as an "aversion score." Thus, the CR was avoidance of the acid-paired compartment. By contrast, mice treated with vehicle in both compartments did not change their preference.

![Assays of pain-related CPA can dissociate analgesics from nonanalgesics. (A and B) Effects produced in mice by the *μ* opioid receptor agonist analgesic morphine (A) or the *κ* opioid receptor agonist nonanalgesic U50,488 (B) in mice also conditioned with intraperitoneal (IP) acetic acid (AA) or in vehicle-treated controls (V). Abscissae show the dose in milligrams per kilogram. Ordinates are the aversion score expressed as time in seconds in the acid- or vehicle control-paired compartment after conditioning minus time in that compartment before conditioning. AA administered alone produced a CPA, whereas V did not. Morphine blocked acid-induced CPA in acid-treated mice more potently than it produced a conditioned place preference in vehicle-treated mice. Filled points in (A) indicate a significant difference from V or AA after morphine treatment (*P* \< 0.05). Conversely, U50,488 failed to alter either acid-induced CPA in acid-treated mice or preference in the vehicle-treated mice. U50,488 was tested up to doses that blocked acid-stimulated stretching (see [Fig. 1](#F1){ref-type="fig"}). Data adapted from [@B16].](pr.118.017210f4){#F4}

Once parameters were established that reliably produced CPA as a CR, then drugs were tested for their effectiveness to block development of that CPA in separate groups of animals. [Figure 4](#F4){ref-type="fig"} shows that administration of morphine prior to acid-conditioning sessions dose-dependently blocked development of the acid-induced CPA, whereas treatment with the *κ* agonist U50,488 did not. Importantly, both drugs were administered at doses sufficient to block the acid-induced UR (acid-stimulated stretching; see [Fig. 2](#F2){ref-type="fig"}). The effectiveness of morphine to block both the acid-induced UR and acid-induced CPA is consistent with both 1) the conclusion that morphine blocked sensory sensitivity to acid as a noxious stimulus and 2) the clinical effectiveness of morphine as an analgesic in humans. By contrast, the failure of U50,488 to block acid-induced CPA suggests that U50,488 did not block sensory sensitivity to the acid noxious stimulus; this again is consistent with the conclusion that U50,488 decreased acid-stimulated stretching in [Fig. 2](#F2){ref-type="fig"} by producing motor impairment and with the failure of centrally acting *κ* agonists as effective analgesics in humans.

This study also included another important control by evaluating effects of both drugs in mice that received only acid vehicle in both compartments during conditioning sessions. Thus, these mice received only vehicle in one compartment and only morphine or U50,488 in the other compartment during conditioning. Test sessions then provided an opportunity to evaluate conditioning effects of the drugs alone in the absence of the noxious stimulus. A high dose of 3.2 mg/kg morphine increased preference for the drug-paired compartment. This type of effect is known as a conditioned place preference (CPP), and it suggests two conclusions. First, this finding raises the possibility that morphine-induced blockade of the acid-induced CPA could have reflected a nonselective increase in preference for the morphine-paired compartment rather than a blockade of sensitivity to the acid stimulus; however, the 10-fold higher potency of morphine to block acid-induced CPA than to produce a CPP in the absence of acid argues against this possibility. Second, drug-induced CPP is often associated with abuse liability, and in this case, the effectiveness of morphine to produce a CPP is consistent with the known abuse liability of morphine ([@B261]). In contrast to morphine, U50,488 had no effect when tested in the absence of the acid noxious stimulus. Notably, U50,488 and other centrally acting *κ* agonists can produce CPA when administered alone in place-conditioning procedures ([@B236]; [@B57]), but the single U50,488 conditioning session used in this study was not sufficient to produce a CPA. Accordingly, the failure of U50,488 to block acid-induced CPA in this study cannot be attributed to aversive effects of U50,488 alone that might have obscured any antinociceptive effects.

[Table 3](#T3){ref-type="table"} summarizes effects of this and other studies that have examined effects of morphine in assays of pain-related CPA. Morphine has consistently been found to block pain-related CPAs at doses that failed to produce a CPP in the absence of the pain state. In the only exception shown in [Table 3](#T3){ref-type="table"}, continuous morphine treatment of 24 hours (via a subcutaneously implanted morphine pellet) failed to block movement-induced CPA in a model of "break-through" bone cancer pain, but a relevant methodological distinction of this study was the sustained presence of morphine during conditioning in both compartments as well as during testing rather than during the conditioning sessions only ([@B87]). Other *μ* agonists have also been found to block pain-related CPA ([@B226]), and in assays that used an inflammatory pain stimulus, NSAIDs were also effective to block pain-related CPAs without producing a CPP in the absence of the pain state ([@B226]; [@B16]). Taken together with data summarized above to show that the *κ* agonist U50,488 failed to block a pain-related CPA ([@B16]), these data suggest that CPA procedures are both sensitive and selective for detecting analgesic drugs; however, this conclusion should be considered preliminary, given the limited number of published studies and limited range of tested drugs. [Figure 5](#F5){ref-type="fig"} provides a schematic to show the four different types of treatment groups that are typically required in a CPA study, together with the different types of effects that are possible with each treatment and how those treatment profiles can be interpreted.

###### 

Effects of *μ*-opioid agonist analgesics (e.g., morphine) in assays of pain-related CPA

  Subject                        Pain Stimulus (Time before Conditioning)                       Conditioning Sessions   Morphine     Result                Reference                                                                                 
  ------------------------------ -------------------------------------------------------------- ----------------------- ------------ --------------------- ----------- ----------------------------------------------------------------------------- ---------
                                                                                                                        *min*        *mg/kg*               *min*                                                                                     
  Rats                           Spinal nerve ligation (−3 wk) +  von Frey (1/min × 15 min)     10                      20 (2/day)   0.3, 3 (s.c.)         −45         Blocked CPA without CPP[*^a^*](#t3n1){ref-type="table-fn"}                    [@B92]
  Rats                           Intraplantar carrageenan (−4 h) +  von Frey (1/min × 15 min)   2                       20 (2/day)   0.3, 3 (s.c.)         −45         Blocked CPA without CPP[*^a^*](#t3n1){ref-type="table-fn"}                    [@B92]
  Male SD rats                   Intraplantar carrageenan (−4 h)                                2                       40           0.005--10 (i.p.)      −15         Blocked CPA; less potent  to produce CPP[*^a^*](#t3n1){ref-type="table-fn"}   [@B265]
  Male SD rats                   Intraplantar CFA (−2 h)                                        2                       30 (2/day)   0.5--1.0 (i.p.)       −30         Blocked CPA without CPP[*^a^*](#t3n1){ref-type="table-fn"}                    [@B292]
  Male ICR mice                  Intraperitoneal acid (0 min)                                   2                       40 (2/day)   0.1--3.2 (s.c.)       −15         Blocked CPA; less potent  to produce CPP[*^a^*](#t3n1){ref-type="table-fn"}   [@B16]
  Male/female SD rats            Intraplantar formalin (0 min)                                  2                       45           0.5--4.0 (s.c.)       −15         Blocked CPA without CPP[*^a^*](#t3n1){ref-type="table-fn"}                    [@B85]
  Male/female Fischer 344 rats   Bone cancer (−11 days) +  leg movement (0 min)                 2                       30 (2/day)   75-mg pellet (s.c.)   −1 day      Did not block CPA                                                             [@B87]
  Male SD rats                   Intraplantar formalin (0 min)                                  2                       60 (2/day)   1, 10 nmol (vBNST)    −10 min     Blocked CPA without CPP[*^a^*](#t3n1){ref-type="table-fn"}                    [@B147]

ICR, Institute of Cancer Research; SD, Sprague-Dawley; vBNST, ventral bed nucleus of the stria terminalis.

These results indicate an antinociceptive drug profile.

![Common experimental groups and drug-effect profiles in assays of pain-related CPA. (A--D) Common conditioning regimens in each of the two compartments of a place-conditioning apparatus during conditioning. The circle with slash indicates the control treatment (e.g., no treatment or vehicle administration), PS is the pain stimulus treatment, and drug is the test-drug treatment. (E--H) Common drug-effect profiles produced by each of these conditioning regimens, and possible interpretations of each drug-effect profile are also shown in each panel. Abscissae are the conditioning regimen as shown in (A) through (D). Ordinates show aversion/preference scores expressed as time in the main treatment-paired compartment after conditioning minus time in that compartment before conditioning. Bars below and above the abscissa indicate a CPA or CPP, respectively.](pr.118.017210f5){#F5}

"Fear-conditioning" and "conditioned-taste-aversion" procedures represent other categories of classical conditioning procedures that engender classically conditioned avoidance learning and that can be used in preclinical pain research ([@B49]; [@B133]). In fear conditioning, the CR is typically an arrest of movement or "freezing" response (i.e., avoidance of locomotion), whereas in taste aversion, the CR is usually reduced consumption of a liquid with a distinctive taste. Both fear-conditioning and conditioned-taste-aversion procedures commonly use non-noxious aversive stimuli as the US, but noxious stimuli can also be used. In an example of a fear-conditioning study using a noxious stimulus as the US ([@B278]), rats were individually transported to a testing room in a plastic bucket and held in the bucket for 30 minutes before placement for 30 seconds into a test chamber with a copper floor that could be heated to various temperatures. The visual and other stimuli inherent to the bucket and test chamber served as the CS, and noxious floor temperatures (50, 52, or 54°C) served as the PS sufficient to elicit paw licking as the UR indicative of nociception. Conditioning consisted of one pairing of CS+PS. Testing occurred 1 day later by again exposing rats to the CS (i.e., 30 minutes in the bucket, followed by placement in the chamber); however, on the test day, the floor was not heated, rats were placed on a small platform above the floor, and the latency to step down off the platform onto the unheated floor was measured. Rats conditioned with CS+PS displayed longer step-down latencies than control rats. Thus, the CR was a delayed step-down response interpreted as evidence of "fear." The effects of both morphine and the GABA~A~ receptor positive allosteric modulator diazepam were evaluated on development of this "fear" CR by administering morphine or diazepam prior to the conditioning trial. During conditioning, morphine pretreatment decreased the heat-induced paw-licking UR, whereas diazepam did not. However, during testing, the delayed step-down CR was reduced for both drugs (i.e., rats treated with either morphine or diazepam during conditioning stepped down more quickly than rats treated with vehicle during conditioning). This profile of results was interpreted to suggest that morphine blocked conditioning by blocking sensitivity to the thermal PS (i.e., antinociception), whereas diazepam did not block thermal sensitivity but produced learning impairment that blocked consolidation of the CS+US association.

Studies of classical conditioning with noxious stimuli as the US have two principal advantages for analgesic drug development. First, from the perspective of preclinical drug assessment, test drug effects can be evaluated on both 1) the noxious stimulus--induced UR during conditioning sessions when the drug is present and 2) the CR during the subsequent test session when the drug is absent. An effective analgesic that blocks sensory sensitivity to the noxious stimulus (i.e., a true analgesic like morphine) will decrease both the UR and the CR. By contrast, blockade of the UR but not the CR (e.g., U50,488 in the CPA experiment described above; [@B16]) suggests a nonanalgesic effect such as motor impairment. Reciprocally, blockade of the CR but not the UR (e.g., diazepam in the fear-conditioning experiment described above; [@B278]) suggests learning impairment.

A second advantage of research on classically conditioned pain behaviors is that they rely on supraspinal neural circuits distinct from the spinal and brainstem neural circuits that mediate many unconditioned pain-stimulated behaviors. For example, the first study to use a pain-related CPA procedure evaluated the effects not of an analgesic drug but of lesions to the rostral anterior cingulate cortex, a brain region thought to be important in processing "affective" as opposed to "sensory" dimensions of pain ([@B102]). In this study, intraplantar injection of formalin served as the PS both to elicit paw licking and flinching behavior as a UR and to produce CPA as a CR. Lesions to the rostral anterior cingulate cortex failed to block the paw licking/flinching UR but did block development of the CPA CR. These results were interpreted to suggest that the rostral anterior cingulate cortex is necessary for either detection or learning of the "aversiveness" of the formalin stimulus but not for the paw licking/flinching reflexive responses. A series of more recent studies has elaborated on the supraspinal neural circuits that underlie pain-related CPA ([@B256]; [@B52], [@B51]; [@B274]) and demonstrated that morphine microinjection into the bed nucleus of the stria terminalis was also sufficient to block formalin-induced CPA without blocking formalin-induced paw licking/flinching ([@B147]). Taken together, these results provide further evidence that different pain behaviors can have different neural mechanisms and respond differentially to pharmacological treatments.

A final advantage of classical conditioning procedures is that classical conditioning plays a role in shaping the human experience of pain ([@B100]; [@B137]; [@B86]), and determinants of the development, expression, and pharmacological modulation of these classical conditioning effects can be examined in preclinical studies. A detailed discussion of the literature on this topic is beyond the scope of this review, but the basic principle is that human experience often includes concurrent exposure to initially neutral stimuli in conjunction with noxious stimuli (e.g., the appearance and smell of a medical facility paired with a painful surgical procedure). By the principles of classical conditioning, these neutral stimuli can come to function as CSs producing pain-related CRs that are either unpleasant in their own right (e.g., anxiety, fear) or that complicate further treatment (e.g., avoidance of the medical facility where treatment is provided). In this regard, drugs such as diazepam may have utility in clinical pain management not because they block sensitivity to noxious stimuli, but because they block conditioned associations between those stimuli and other neutral stimuli in the environment, thereby attenuating development of undesirable CRs.

Two weaknesses will be mentioned for studies that use a noxious stimulus as the US in classical conditioning. First, as noted above, test drugs can block the formation of a pain-related CR not only by blocking sensory sensitivity to the US, but also by blocking sensitivity to the CS or by impairing the formation of new memories. Blockade of sensitivity to the CS is likely a minor issue in most studies of pain-related conditioning because the CS is often a compound stimulus with components in multiple stimulus modalities. For example, in place-conditioning studies, the CS often consists of both visual and tactile stimuli. Nonetheless, the potential for false-positive effects due to impaired sensitivity to the CS should be considered. The more significant risk of false-positive effects lies in treatments that impair learning, and although blockade of pain-related associations may have some clinical benefit, it is not the goal of most analgesic drug development programs. There are several strategies to evaluate the potential role of learning deficits in studies that examine drug effects on pain-related CRs. For example, [@B265] found that morphine blocked development of a pain-related CPA when the morphine was administered before the PS during a conditioning session, but not when it was administered immediately after the conditioning session. This finding was interpreted to suggest that morphine blocked sensory sensitivity to the PS during conditioning, but it did not alter memory consolidation processes occurring in the period after the conditioning session. As another example, [@B16] found that morphine blocked development of a pain-related CPA but not CPA to a non-noxious aversive stimulus (lithium chloride injection), suggesting that morphine produced a selective decrease in pain-related learning rather than a general impairment of all learning. Lastly, as noted above, drug effects can be compared on both initial expression of the PS-elicited UR during conditioning and on subsequent expression of the CR during testing. Clinically effective analgesics generally block both the UR and CR, whereas learning impairment should be considered if only the CR is blocked.

A second challenge in classical conditioning studies is optimal temporal alignment of the CS and PS during conditioning sessions. Alignment of CS and PS can be most precisely controlled with stimuli that have rapid onsets, short durations, and rapid offsets, and the optimal arrangement is usually a form of delay conditioning as shown in [Fig. 3](#F3){ref-type="fig"}. However, pain stimuli often have relatively slow onsets, long durations, and variable offsets that can complicate conditioning. For example, many of the studies of pain-related CPA summarized in [Table 3](#T3){ref-type="table"} used chemical stimuli (intraplantar formalin, intraplantar carrageenan, intraperitoneal acid), with onsets of seconds to minutes, durations of minutes to hours, and poorly defined offsets. However, no published studies have systematically examined the role of stimulus alignment in producing pain-related CPAs. For example, delay conditioning involves presentation of the CS for some period of time before and during the US, but in general, the studies in [Table 3](#T3){ref-type="table"} delivered the PS immediately before confinement to the pain-paired compartment, so there was little if any explicit opportunity for CS exposure prior to PS onset. It is reasonable to suppose that longer CS exposure prior to PS delivery might produce either more robust CPA or CPA with lower PS intensities, but data to address this issue have not been published. Similarly, the duration of conditioning sessions for studies in [Table 3](#T3){ref-type="table"} were 20--60 minutes, but the role of session duration as a determinant of pain-related CPA has also not yet been systematically studied. Temporal alignment of CS and PS is even more challenging with putative chronic pain states, such as in models of chronic inflammatory or neuropathic pain thought to produce pain lasting days, weeks, or months. In humans, chronic inflammatory and neuropathic states are often characterized by spontaneous pain (i.e., pain in the absence of other overt evocative stimuli), but the timing of spontaneous pain episodes cannot be precisely controlled in the laboratory and accordingly cannot be used as a reliable US in classical conditioning studies. Rather, it is necessary in CPA models of chronic pain to also incorporate an acute evocative stimulus that can be more precisely controlled. For example, [@B92] engendered CPA in rats treated with either an inflammatory or neuropathic insult hours or weeks, respectively, before any conditioning. As a result, any spontaneous pain associated with the inflammatory/neuropathic injury was present during conditioning in both compartments as well as during testing, and hence could not serve as the US. To produce CPA, these investigators supplemented the underlying inflammatory/neuropathic pain stimulus with mechanical stimulation (probing the hindpaws with a relatively high-force von Frey filament) that was paired with only one compartment. Accordingly, in this study, the US consisted of the inflammatory/neuropathic stimulus + acute mechanical stimulation, and CPA presumably depended on hypersensitive pain responses to mechanical stimulation. Similarly, [@B87] established a CPA in rats using a US consisting of an underlying model of bone cancer supplemented by subsequent acute mechanical stimulation (manual articulation of the affected hindlimb) that was paired with one compartment.

### 3. Pain Stimulus as a Contextual Stimulus {#s12}

In a second type of classical conditioning study, the noxious "pain" stimulus functions as a contextual stimulus that modulates conditioning with other non-noxious stimuli. This role can be expressed as follows:Although many permutations of this approach are possible, perhaps the most popular is guided by the supposition that just as pain onset can be aversive and produce a CPA, so pain offset can be rewarding and produce a CPP ([@B237]; [@B253]; [@B114]). Thus, in this type of experimental design, the PS serves as a contextual stimulus intended to produce an underlying pain state, and the US is a drug or other treatment hypothesized to terminate that pain state. For example, one study compared place-conditioning effects of intrathecal clonidine and intrathecal adenosine in rats with a spinal nerve ligation model of neuropathy ([@B114]). Ten days after nerve ligation or sham surgery, rats received two conditioning sessions, in which intrathecal saline was paired with one compartment of a place-conditioning apparatus, and intrathecal clonidine or adenosine was paired with the other compartment. During a test session the day after conditioning, rats received no treatments, and allocation of time between the two compartments was assessed. Intrathecal clonidine produced a CPP in the rats with nerve ligation but not in the sham-operated controls, whereas intrathecal adenosine failed to alter preferences in either group. These results were interpreted to suggest that nerve ligation produced a chronic and aversive neuropathic pain state that was alleviated by intrathecal administration of clonidine but not adenosine. These results were also considered to be consistent with clinical experience indicating that intrathecal clonidine, but not intrathecal adenosine, is an effective treatment of some types of neuropathic pain. [Figure 6](#F6){ref-type="fig"} provides a schematic to show the four different types of treatment groups that are typically required in a CPP study, together with the possible outcomes with test drugs and how those treatment outcomes can be interpreted.

![Common experimental groups and drug-effect profiles in assays of drug-induced CPP in subjects with a putative pain state as a contextual stimulus. (A--D) Common conditioning regimens in each of the two compartments of a place-conditioning apparatus during conditioning. The circle indicates the control treatment (e.g., no treatment or vehicle administration), PS is the pain stimulus as contextual stimulus that is present or absent in both compartments, and drug is the test-drug treatment. (E--H) Common drug-effect profiles produced by each of these conditioning regimens, and possible interpretations of each drug-effect profile are also shown in each panel. Abscissae are the conditioning regimen as shown in (A) through (D). Ordinates are the aversion/preference scores expressed as time in the main treatment-paired compartment after conditioning minus time in that compartment before conditioning. Bars below and above the abscissa indicate a CPA or CPP, respectively.](pr.118.017210f6){#F6}

The main strength of the CPP experimental design as a classical conditioning procedure is its potential for evaluating pharmacological relief of chronic spontaneous pain. As noted above, putative chronic pain states produced by manipulations such as inflammation or nerve injury are unwieldy as the US in classical conditioning procedures because the onset and duration of the pain state are protracted and potentially variable across subjects, and hence difficult to pair precisely with a CS. In CPP studies, the PS is thought to produce a sustained spontaneous pain state that does not require additional evocative stimuli and that is present during all conditioning sessions as well as during testing (see [Fig. 6B](#F6){ref-type="fig"}). The US is not the pain stimulus, but rather a drug hypothesized to produce pain relief. The temporal parameters of these drug stimuli can be controlled as a US for pairing with a CS, and treatments that produce CPP with greater potency or effectiveness in injured animals than in controls provide evidence for both existence of the underlying spontaneous pain state and the relief of that pain state.

An additional strength of this type of procedure, as with all classical conditioning procedures, is that drug effects are evaluated by measuring a CR expressed when the drug is no longer present. As a result, drug effects on motor function (e.g., motor impairment) that might occur during conditioning sessions when drug is present are not expected to confound measurement of CR expression during subsequent test sessions when drug is absent. Also, as with CPA procedures described above, CPP procedures rely on supraspinal circuits thought to be important in the "affective" dimensions of pain, and CPP procedures have been used to dissociate neural circuits that mediate drug-induced CPP from circuits that mediate drug effects on pain-stimulated behaviors ([@B114]; [@B174], [@B173]; [@B109]; [@B276]).

A significant weakness of CPP experimental designs is their unreliable sensitivity to clinically effective analgesics. For example, [Table 4](#T4){ref-type="table"} summarizes studies that have examined morphine effects in CPP procedures. Although analgesic drugs are expected to produce CPP more potently and/or effectively in chronic pain states than in control states, morphine and other *μ* agonist analgesics ([@B170]; [@B163]) often fail to produce this profile. Thus, of the 18 experiments summarized in [Table 4](#T4){ref-type="table"} using a range of different chronic pain manipulations, morphine produced a clear antinociceptive profile in only six experiments; in many studies, the pain manipulations decreased morphine CPP relative to that observed in control subjects. Similarly, NSAIDs also usually fail to produce CPP in subjects with presumed chronic inflammatory pain ([@B237]; [@B253]; [@B254]; [@B201]), although CPP is sometimes observed (e.g., in a K/BxN serum transfer model of rheumatoid arthritis; [@B201]). The poor sensitivity of these procedures to detect known analgesics obviously raises concern about their utility for evaluating novel compounds.

###### 

Effects of morphine in assays of analgesia-related CPP

  Subjects                              Pain Stimulus (Time before Conditioning)                            Conditioning Sessions   Morphine     Result                Reference                                                                                     
  ------------------------------------- ------------------------------------------------------------------- ----------------------- ------------ --------------------- --------------------------------- ----------------------------------------------------------- ---------
                                                                                                                                    *min*        *mg/kg*               *min*                                                                                         
  Male SD rats                          Intraplantar CFA                                                    6                       60           0.3--5.6 (s.c.)       −0                                CPP in pain = nonpain                                       [@B237]
  Male SD rats                          Intraplantar CFA (−1 day)                                           8                       60           3--10 (i.p.)          −0                                CPP in pain = nonpain                                       [@B253]
  Male SD rats                          Intraplantar carrageenan (−1 day), intraplantar formalin (−1 day)   4                       50           2--8 (i.p.)           −0                                No CPP in pain, CPP in  nonpain                             [@B254]
  Male SD rats                          Partial nerve ligation (−4 days)                                    6                       60           4--8 (s.c.)           −0                                No CPP in pain, CPP in  nonpain                             [@B197]
  Male C57Bl/6J mice                    Partial nerve ligation (−4 days)                                    6                       30 (2/day)   2.5--5 (s.c.)         −0                                No CPP in pain, CPP in  nonpain                             [@B210]
  Female C57Bl/6J mice                  Intraplantar carrageenan (−4 h)                                     6                       20 (2/day)   10 (i.p.)             −5                                CPP in pain = nonpain                                       [@B25]
  Intraplantar CFA (−4 h)               6                                                                   20 (2/day)              10 (i.p.)    −5                    No CPP in pain, CPP in  nonpain   [@B25]                                                      
  Intraplantar tumor cells (−20 days)   6                                                                   20 (2/day)              10 (i.p.)    −5                    No CPP in pain, CPP in  nonpain   [@B25]                                                      
  Male/female Tg mice                   Partial nerve ligation (−3 days)                                    6                       60           5 (s.c.)              −0                                CPP in pain \< nonpain                                      [@B192]
  Male SD rats                          Spinal cord contusion (−2 days)                                     4                       45 (2/day)   1.25, 2.5 (?)         −0                                CPP in pain ≥ nonpain[*^a^*](#t4n1){ref-type="table-fn"}    [@B284]
  Male SD rats                          Paclitaxel treatment (−7 days), Oxaliplatin treatment (−7 days)     6                       60           4 (s.c.)              −0                                CPP in pain ≤ nonpain                                       [@B163]
  Female Tg mice                        Intraplantar CFA (−3 days)                                          6                       30 (2/day)   0.1 (i.p.)            −0                                CPP in pain ≥ nonpain[*^a^*](#t4n1){ref-type="table-fn"}    [@B293]
  Male SD rats                          Spinal nerve ligation (−21 to −14 days)                             2                       30 (2/day)   0.5, 4.0 (i.v.)       −0                                CPP in pain ≥ nonpain[*^a^*](#t4n1){ref-type="table-fn"}    [@B174]
                                        Spinal nerve ligation (−21 to −14 days)                             2                       30 (2/day)   20 *μ*g/side          −0                                CPP in pain ≥ nonpain[*^a^*](#t4n1){ref-type="table-fn"}    [@B174]
                                        Paw incision (−1 day)                                               2                       30 (2/day)   20 *μ*g/side (rACC)   −0                                CPP in pain ≥ nonpain[*^a^*](#t4n1){ref-type="table-fn"}    [@B174]
  Male/female C57BI/6 mice              Paclitaxel treatment (−3 days)                                      6                       30           0.3--10 (i.p.)        −15                               CPP in pain = nonpain                                       [@B177]
  Male LE rats                          Peripheral nerve injury (−6 days)                                   8                       30           1--8 (s.c.)           −0                                CPP in pain ≥ nonpain[*^a^*](#t4n1){ref-type="table-fn"}    [@B33]
  Male/female SD rats                   Intraplantar CFA (−1 days)                                          2                       45           1--12 (s.c.)          −0                                CPP in pain ≤ nonpain                                       [@B9]
                                        Intraplantar CFA (−7 days)                                          2                       45           1--8 (s.c.)           −0                                CPP in pain \> nonpain[*^a^*](#t4n1){ref-type="table-fn"}   [@B9]

LE, Long-Evans; rACC, rostral anterior cingulate cortex; SD, Sprague-Dawley; Tg, transgenic.

These results indicate an antinociceptive drug profile.

The reasons for this poor sensitivity remain to be determined, but one factor may be the dependence of classical conditioning on temporal alignment of the US and CS. [Table 4](#T4){ref-type="table"} suggests that morphine has been most effective to produce an antinociceptive CPP profile when relatively low doses are administered by a route of administration that produces rapid onset of drug effects (i.e., intravenous or intracranial), and conditioning sessions are relatively short. However, [Table 4](#T4){ref-type="table"} also shows exceptions to this hypothesis. More systematic parametric studies would be required to clarify the importance of these variables for morphine effects, and the prospect of addressing these issues with every new test drug is daunting.

An alternative approach has been to establish an "analgesia-selective" CPP using some other treatment, and then to evaluate the effectiveness of a test drug to block CPP by that treatment. In one study, for example, peripheral nerve block with the local anesthetic lidocaine produced CPP in rats with a model of bone cancer pain but not in control rats ([@B218]). This lidocaine-induced CPP was blocked by systemic morphine (a 75-mg pellet implanted subcutaneously the day before conditioning), and this finding was interpreted to suggest that morphine produced a sustained analgesia that blocked effectiveness of lidocaine to produce any additional analgesia that might serve as a US and maintain CPP. However, this approach is logistically complicated insofar as it requires a chronic pain state (and controls), a treatment sufficient to produce reliable CPP in that pain state (and controls), and administration of the test drug during all conditioning sessions (i.e., in both compartments during conditioning). Moreover, interpretation of drug effects produced by novel compounds can be complicated because CPP induced by the effective treatment can be blocked not only by analgesia to overshadow effects of that treatment but also by manipulations that block its antinociceptive mechanisms. For example, peripheral nerve block-induced CPP in rats with either paw-incision or spinal nerve ligation injuries could be blocked by administration of the opioid antagonist naloxone into the rostral anterior cingulate cortex ([@B174]). The interpretation here was not that naloxone produced analgesia that overshadowed effects of the peripheral nerve block; rather, the results were interpreted to suggest that naloxone blocked opioid receptor signaling that mediated effects of the nerve block.

A second weakness of CPP procedures in preclinical pain research is the absence of direct evidence for existence of the pain state independent of drug effects. The value of CPP procedures lies in their intended utility to evaluate sustained spontaneous pain states thought to result from inflammatory, neuropathic, or other chronic pain manipulations. However, as noted above, many manipulations intended to produce chronic pain turn out to have little or no effect on spontaneous behaviors (e.g., little or no evidence of unconditioned pain-stimulated or pain-depressed behavior). As a result, in contrast to CPA procedures that use noxious stimuli with clear URs, there is little opportunity in CPP procedures to compare drug effects on pain-related URs with pain-related CRs. As an alternative, many studies compare drug-induced CPP effects with drug effects on hypersensitive URs elicited by evocative stimuli such as von Frey filaments; however, this is an apples-to-oranges comparison of drug effects on putative manifestations of spontaneous versus evoked pain, which are considered a priori to be distinct (e.g., [@B218]; [@B87]). Additionally, the possibility also exists that any aversive state produced by putative "chronic pain" insults may reflect sensations other than pain such as nonpainful dysesthesias (e.g., tingling, itch), and drug-induced CPP may reflect relief of those aversive but nonpainful states rather than relief of pain. For example, the effectiveness of gabapentin to produce CPP in rodents with neuropathic insults ([@B202]; [@B19]) is not consistent with its relatively weak effectiveness to treat neuropathic pain ([@B198]; [@B70]), but may be related to its effectiveness to treat neuropathy-associated itch ([@B136]). Moreover, the poor sensitivity of CPP procedures to *μ* agonists and NSAID analgesics suggests that the underlying aversive state may be something other than pain.

A final weakness of CPP procedures, as with CPA procedures, is their vulnerability to false-positive effects with treatments that impair learning. For example, [@B253] found that neither morphine nor indomethacin produced an antinociceptive CPP profile in rats treated with intraplantar CFA to induce a putative inflammatory pain state; however the *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) glutamate receptor antagonist (5*R*,10*S*)-(+)-5-methyl-10,11-dihydro-5*H*-dibenzo\[*a*,*d*\]cyclohepten-5,10-imine (MK-801) did produce a CPP.[^1^](#fn1){ref-type="fn"} This result was interpreted as evidence for pain relief by MK-801; however, MK-801 and other NMDA receptor antagonists are also well known to impair some types of neural plasticity and learning ([@B164]; [@B186]), and as a result, MK-801--induced CPP may also have reflected learning impairment.

### 4. Summary {#s13}

In summary, the primary application of classical conditioning procedures to preclinical analgesic drug development has involved place-conditioning procedures to study either 1) drug effects on pain-related place aversion or 2) drug-induced conditioned place preferences in the context of a putative pain state. However, other classical conditioning procedures (e.g., fear-conditioning and conditioned-taste-aversion procedures) can also be used. Before concluding the section on classical conditioning in preclinical pain research, three other points warrant mention. First, it is theoretically possible for the pain stimulus to play the role of CS in a classical conditioning experimental design. This role would be designated as follows: 1) PS+US; 2) PS→CR. Although this type of design has not been used in preclinical studies, possible examples in human pain experience might include the potential for negative associations between pain stimuli and other aversive events, such as unemployment. In these cases, pain stimuli may elicit conditioned responses of exaggerated anxiety or fear, and analgesics may not eliminate all features of the pain stimulus that elicit negative conditioned responses. There is also potential for positive associations between noxious stimuli and rewarding stimuli that can occur during exercise (e.g., when athletic success serves as the US), intravenous drug abuse with a hypodermic needle (e.g., where the US is the effect of the abused drug), or masochism (e.g., where the US is sexual activity). Pain stimuli participating as the CS in positive associations may produce a conditioned response of pleasure rather than pain, and analgesic drugs would not be used to reduce such conditioned responses.

Second, it is also possible to use noxious stimuli as contextual stimuli in studies to examine pain effects on learning and cognitive function. Clinical pain states have been associated with various cognitive deficits due, for example, to allocation of attention toward pain sensations and away from other external or internal stimuli that might normally be detected and integrated into new learning ([@B257]; [@B151]). For example, one study evaluated the effects of paw incision in a model of fear conditioning in mice ([@B291]). Mice were initially given either a paw-incision or sham surgery to produce a sustained pain state as a contextual stimulus. Twenty-four hours later, mice were exposed to a classical conditioning regimen in which a tone CS was paired with a brief foot shock US. During testing the next day, the CS alone produced "freezing behavior" as the CR, and expression of this CR was attenuated in the mice with paw incision. This finding supported other evidence to suggest that paw incision produced a hippocampus-independent learning impairment associated with reduced NMDA receptor expression in the prefrontal cortex. Analgesic treatment before the conditioning would presumably prevent this pain-related learning impairment, but these types of experimental designs have not yet been used to evaluate effects of candidate analgesic drugs.

Lastly, classical conditioning of analgesic responses can contribute to clinical treatment responses. For example, CSs paired with analgesic drug delivery can come to elicit an analgesic CR in the absence of the analgesic drug (i.e., the "placebo response"; [@B213]; [@B79]; [@B14]). The determinants of classical conditioning effects and their interactions with candidate analgesic drugs can be examined in preclinical procedures that use pain stimuli as a contextual stimulus and analgesic drugs as the US ([@B22]; [@B153]).

C. Operant Conditioning {#s14}
-----------------------

### 1. Definition {#s15}

Operant conditioning is a type of learning in which behavior is shaped by its consequences according to a "three-term contingency" ([@B241]; [@B211]). The arrangement of these three terms can be diagrammed as follows:where S^D^ denotes a discriminative stimulus, R denotes a behavioral response by the subject, and S^C^ denotes a consequent stimulus delivered to the subject as a consequence of its behavior. In a preclinical example of operant conditioning, a mouse or rat can be placed into a chamber equipped with stimulus lights, a response lever, and a trough where food pellets can be delivered. Contingencies can then be established such that when the stimulus lights are illuminated (the S^D^), then performance of lever-pressing behavior (the R) results in delivery of a food pellet (the S^C^), whereas when the stimulus lights are off, then lever-pressing does not produce food delivery. Under these conditions, subjects will generally learn to respond on the lever when the stimulus lights are illuminated but not when the lights are off.

Operant conditioning plays a major role in shaping the behavior of humans as well as laboratory animals. In an example of human behavior analogous to the animal behavior described above, illumination of the distinctive sign of a fast-food restaurant (the S^D^) indicates that performance of a behavioral response (placing and paying for an order at the counter, the R) will result in delivery of the ordered food (the S^C^). Operant conditioning is also involved in the acquisition and maintenance of many other behaviors as diverse as speaking a language, driving a car, or seeking treatment for an injury. In general terms, the probability of a behavior increases if it produces positive outcomes and decreases if it produces negative outcomes. Stated more formally, consequent stimuli (like food delivery in the examples above) that increase the probability of the preceding behavior are considered to function as "reinforcers," whereas consequent stimuli that decrease the probability of the preceding behavior are considered to function as "punishers."

In both humans and in preclinical studies using operant-conditioning procedures in animals, pain stimuli can serve in one of three different stimulus roles: 1) as the S^D^, 2) as the S^C^, or 3) as a contextual stimulus that modifies behavior maintained by contingencies involving other types of S^D^ and S^C^. Test drugs can then be evaluated for their effectiveness to block either the discriminative-, consequent-, or contextual-stimulus effects of the pain stimulus.

### 2. Pain Stimulus as the Discriminative Stimulus {#s16}

Perhaps the most intriguing and misunderstood role of pain stimuli in operant conditioning is in their role as a discriminative stimulus according to the following relationship:where PS again denotes the pain stimulus. In this role, the presence of the pain stimulus PS signals that performance of behavioral response R will produce a consequent stimulus S^C^ that typically functions as a reinforcer. Conversely, when the PS is absent, then R does not produce S^C^. The use of a pain stimulus as the S^D^ in preclinical research is exceedingly rare and may be unfamiliar to many preclinical researchers; however, as will be discussed in more detail below, this is by far the most common role of pain stimuli in human pain assessment. This massive discordance between preclinical and clinical studies in their focus on pain discrimination is a major obstacle to effective translational research.

Discrimination procedures are commonly used in laboratory animals to evaluate perception of nonpain stimuli. For example, in drug-discrimination procedures, a drug of interest serves as the discriminative stimulus, and drug discrimination in animals correlates well with the subjective (i.e., verbally described) effects of drugs in humans ([@B196]; [@B228]; [@B11]; [@B34]). In one of the rare preclinical examples of noxious-stimulus discrimination, rhesus monkeys responded during daily operant behavioral sessions consisting of discrete trials ([@B258]). Each trial began when the monkey pressed and held a response key. Beginning at a variable time (3--9 seconds) after trial initiation, a thermode attached to the subject's upper lip delivered a noxious heat stimulus consisting of a rapid increase in temperature of 0.4, 0.6, or 1.0°C from a baseline of 46°C. Release of the response key within 2.4 seconds of the heat stimulus produced juice delivery. Thus, in this procedure, the increase in thermode temperature served as the pain-related S^D^, release of the response key within 2.4 seconds served as the R, and juice delivery served as the S^C^. If the response occurred in the absence of the S^D^ (i.e., before or more than 2.4 seconds after the heat stimulus), then juice was not delivered. Training in this task took several months, and once training was completed, the effects of morphine pretreatment were determined. Morphine produced antinociception insofar as it produced a dose-dependent decrease in thermal stimulus discrimination (i.e., after morphine treatment, monkeys failed more often to release the response key within 2.4 seconds of stimulus delivery, and therefore failed to earn juice delivery). Moreover, morphine effects were dependent on both stimulus intensity (the small heat-stimulus increase of 0.4°C was more sensitive to morphine antinociception than the higher stimulus increases of 0.6 and 1.0°C) and stimulus modality (similar discrimination of a visual stimulus was not altered by morphine).

This approach to preclinical analgesic testing clearly presents many challenges, two of which are especially problematic. First, discrimination training is at best time-consuming, and in this case, took months to achieve before drug testing could commence. At worst, discrimination training might not be possible. For example, my laboratory has been unable to establish accurate discrimination performance of a visceral noxious stimulus (intraperitoneal acid) in rats using a two-lever discrimination procedure similar to procedures commonly used in studies of drug discrimination ([@B196]; [@B42]; [@B34]). Second, the requirement for extended training necessarily requires repeated exposure to the noxious stimulus, and this can complicate protocol approvals by regulatory agencies and alter nociceptive physiology and behavior by producing sensitization, inflammation, or neuropathy. These and other challenges have no doubt contributed to the dearth of preclinical research with noxious-stimulus discrimination.

Weighed against these two significant weaknesses are two potential strengths. First, preclinical pain-discrimination procedures can theoretically display high selectivity to distinguish between analgesics and drugs that produce nonselective behavioral disruption due to impaired motor function, motivation, or attention. In the procedure described above, for example, the analgesic morphine reduced the accuracy of noxious-heat discrimination without affecting trial initiation or the accuracy of visual discrimination ([@B258]). A nonanalgesic negative control was not tested in these studies, but a nonanalgesic that produced deficits in motor function, motivation, or cognition (e.g., a *κ* agonist) would have been expected to produce a nonselective decrease in rates of trial initiation for both noxious-heat and visual stimuli without necessarily altering the accuracy of responding in trials that were initiated.

A second strength of pain-discrimination procedures lies in their potential to model verbal pain reports in humans. In human pain assessment, the most commonly used endpoints are verbal behaviors guided by instruments such as the 0--10 numeric rating scale or by questionnaires that ask respondents to endorse adjectives to describe their pain ([@B56]; [@B154]). Most human verbal behavior is operant behavior occasioned by discriminative stimuli and maintained by consequent stimuli ([@B240]). For example, in the case of the fast-food restaurant described above, the presence of a distinctive restaurant sign signals that verbal behavior involved in ordering a meal ("Cheeseburger, please") will produce delivery of that meal. Said another way, the restaurant sign as the S^D^ "occasions" the expression of verbal ordering behavior R that is maintained by meal delivery as the S^C^. Restaurant signs are "exteroceptive" stimuli that originate outside the body of the subject who emits the behavior, but operant verbal behavior can also be occasioned by "interoceptive" stimuli originating inside the subject. For example, food deprivation produces a constellation of interoceptive physiologic effects that we might learn to label verbally as "hunger," and the convergence of both exteroceptive stimuli (the restaurant sign) and interoceptive stimuli (physiologic effects of food deprivation) serves as a compound discriminative stimulus to signal not only that ordering a meal will produce a meal, but also that the meal is likely to be valued and consumed once received. This relationship is diagrammed in [Fig. 7](#F7){ref-type="fig"}.

![Verbal behavior as a form of operant behavior. Verbal behavior is often a form of operant responding (R) occasioned by discriminative stimuli (S^D^) and resulting in delivery of consequent stimuli (S^C^). The arrow leading from the consequent stimulus S^C^ back to the verbal behavior R indicates that the consequent stimulus increases the probability of (or "reinforces") the verbal behavior.](pr.118.017210f7){#F7}

Noxious stimuli can also produce a constellation of interoceptive events that can serve as a discriminative stimulus for verbal behavior that may ultimately be reinforced. For example, verbally competent children or adults typically learn through a history of life experiences to use an increasingly sophisticated repertoire of words to describe the intensity, quality, and anatomic location of their internal pain experiences and to guide the delivery of treatment.

[Figure 7](#F7){ref-type="fig"} shows how pain-related verbal behavior might be occasioned by appropriate exteroceptive stimuli (e.g., a clinical context such as a doctor's office) and interoceptive discriminative stimuli (the physiologic and subjective effects produced by a painful injury) and reinforced by effective treatment delivery (e.g., analgesic administration). These verbal reports are the mainstay of human pain assessment, in part because of their ease of collection and their superficial appearance of precision given the presumption that the subject is both 1) in the best position to report on the dimensions of his or her own pain and 2) willing and able to deliver that report with accuracy. However, as with any operant behavior, the expression of verbal pain reporting depends not only on the discriminative stimuli that occasion it, but also on the consequent stimuli that follow it and the history of prior experience that has linked the experience of pain, the expression of verbal pain reports, and the delivery of consequent stimuli. In this regard, verbal pain reports might be unreliable as a pain measure for a variety of reasons. Three will be mentioned here. First, numeric pain-rating scales use the language of numbers (1, 2, 3, etc.), but these numeric labels provide only a qualitative ranking of pain states (i.e., they are ordinal variables rather than more quantitative interval or ratio variables), and they are anchored to a theoretical "worst pain imaginable" that can vary between subjects or within a subject over time ([@B113]). Thus, neither the increments between numeric ratings nor the range of possible ratings can be considered reliably stable within or between subjects. Second, operant conditioning may result in a failure to report pain despite the presence of pain. For example, an injured athlete who reports pain to a coach might lose the opportunity to compete, and such a consequent stimulus might reduce future verbal pain reports despite the presence of pain. Lastly, a reciprocal situation can also occur in which verbal pain reports occur despite the absence of pain. Of particular concern during the present crisis of opioid abuse, a verbal report of pain to an unethical physician might be sufficient to produce delivery of an opioid analgesic even if pain is absent, and that opioid delivery might reinforce future verbal pain reports in the absence of pain. Overall, verbal reporting as a type of pain-discrimination behavior is likely to remain a pillar of human pain assessment because the data are easy to collect and are often useful in guiding treatment; however, even in clinical research, concern over the reliability of verbal reporting has stimulated efforts to incorporate other, more objective metrics such as measures of pain-related functional impairment ([@B56]; [@B53]). Pain-discrimination behavior is much more difficult to assess in laboratory animals.

### 3. Pain Stimulus as the Consequent Stimulus {#s17}

A more common use of noxious stimuli in preclinical operant-conditioning procedures is as the consequent stimulus, and this relationship can be diagrammed as follows:In this role, the pain stimulus PS is delivered only if a particular discriminative stimulus is present and a particular response is emitted by the subject, and the PS generally functions to punish responding (i.e., decrease the probability of the preceding response R). [Figure 8](#F8){ref-type="fig"} shows one example of a preclinical procedure using a noxious stimulus as a consequent stimulus ([@B191], [@B189]; [@B4]; [@B168]). In this procedure, rats are placed into a testing cage (the features of which constitute the S^D^) in which licking from a spout (the R) results in delivery of sweetened condensed milk (the S^C^) through the spout. To gain access to the spout, the subject has to press its face into an aperture lined with metal tubing that can be heated to controlled temperatures either by circulating water from an attached water pump or via a computer-controlled Peltier device. Thus, licking from the spout results not only in delivery of milk via the spout, but also in delivery of a thermal stimulus to the rat's face via contact with the heated surface (an additional S^C^). Under these conditions, noxious thermal stimuli produce temperature-dependent decreases in the numbers of licking responses and milk deliveries. Thus, delivery of noxious thermal stimuli punishes licking behavior (i.e., decreasing the probability of licking). Moreover, thermal sensitivity in this procedure can be sensitized by treatment of facial skin with carrageenan to produce inflammation ([@B4]) or capsaicin to produce neurogenic inflammation ([@B189]), and in both cases, this thermal hypersensitivity to either a 45°C stimulus ([Fig. 8](#F8){ref-type="fig"}) or a higher 48°C stimulus (unpublished data; J. Neubert, personal communication) can be reversed by a low dose of 0.5 mg/kg morphine ([@B191]). [Figure 8](#F8){ref-type="fig"} also shows that the capsaicin-induced hypersensitivity to 48°C thermal punishment can be alleviated by the transient receptor potential V1 antagonist (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo\[b\]\[1,4\]dioxin-6-yl)acrylamide (AMG9810) (30 mg/kg), but not by the *κ* opioid receptor agonist methyl 4-\[2-(3,4-dichlorophenyl)acetyl\]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR89696) ([@B190]). This procedure has also been adapted for use in mice ([@B188]; [@B216]) and for use with noxious mechanical rather than thermal stimuli ([@B221]).

![Noxious stimuli can serve in operant-conditioning procedures as consequent stimuli that punish behavior. The top two panels show photographs of a rat responding in an operant-based method called the Orofacial Pain Assessment Device, which can be used to assess thermal hypersensitivity. In this procedure, the subject must contact the stimulus surface (gold thermode) on either side of an aperture to access a drinking spout containing sweetened milk. The lower panel shows data for operant responding in rats tested in this procedure. Testing was completed for naive (untreated) animals at 45 or 48°C, and rates of operant responding expressed as reward licking events were normalized as a percentage of baseline values at each respective temperature. Increasing temperatures decreased (i.e., punished) responding (data not shown; see [@B191]), and treatment with capsaicin (CAP) (0.1% topical cream) to the cheeks for 5 minutes produced hypersensitivity to thermal punishment, such that responding in rats treated with CAP and drug vehicle (Veh) was even lower after capsaicin treatment. Capsaicin-sensitized thermal punishment was alleviated by morphine (0.5 mg/kg) and by the transient receptor potential V1 antagonist AMG9810 (30 mg/kg; +, *P* \< 0.05 vs. Veh), but not by the *κ*-2 opioid receptor agonist GR89696 (0.125 *μ*g/kg). \**P* \< 0.05 (significant pain-related punishment; i.e., fewer licking contact events than baseline); ^\#^*P* \< 0.05 (antinociception; i.e., significantly more licking contact events after drug than after vehicle). This image was kindly contributed by Dr. John Neubert and adapted from [@B190].](pr.118.017210f8){#F8}

Other types of operant procedures have also been developed to establish thermal or mechanical punishment of operant behavior in rodents ([@B150]; [@B26]; [@B84]) and squirrel monkeys ([@B110]). These procedures include "place-escape/avoidance" procedures, in which subjects locomote within an environment with different zones, and entry into a subset of zones results in the delivery of a putative noxious stimulus (e.g., contact with a cooled or heated thermal plate or delivery of mechanical stimuli to the paw) ([@B207]; [@B74]; [@B47]). These procedures take advantage of unconditioned exploratory behavior in rodents, and as a result, little or no training is required to establish baseline exploratory behavior between zones in the environment. Nonetheless, the procedures are considered here as operant punishment procedures because delivery of the noxious stimuli is contingent on the behavior of the subject (i.e., entry into zones where noxious stimuli are delivered), and delivery of noxious stimuli decreases that behavior. Pain is inferred from a decrease in time spent in the zones where noxious stimuli are delivered, and antinociception is expressed as an increase in this punished behavior.

There are two significant strengths to procedures that assess pain-related punishment of operant responding. First, operant learning with noxious stimuli plays a major role in shaping human behavior in both health and disease, and preclinical studies on expression and pharmacological modulation of these processes can contribute to translational research. In healthy subjects, noxious stimuli serve as robust teaching signals to punish maladaptive behaviors that might cause injury. For example, touching a red-hot stove burner will elicit an immediate withdrawal response as an unconditioned behavior, but that contact with noxious heat also serves as a consequent stimulus to punish future burner-touching behavior when the discriminative stimulus of a red burner is present. In injured or diseased subjects, hypersensitive pain states can also result in punishment of normally innocuous behaviors. For example, in patients with arthritis, normal movements such as walking can stimulate hypersensitive nociceptors in affected joints to punish further walking and produce a general profile of functional impairment ([@B81]; [@B68]). This type of hypersensitivity and punishment of behavior can again confer the adaptive advantage of reducing the probability of behaviors that could further damage the injured or diseased part of the body. However, pain-related punishment can also impede the performance of other adaptive behaviors like caring for children, meeting a job requirement, or escaping from danger. Moreover, movement-induced punishment of behavior can also impede participation in therapeutic physical therapy ([@B105]).

A second advantage of punishment procedures is that noxious stimuli functioning as punishers decrease rates of the target behavior, and as a result, pain-related punishment can be conceptualized as a type of pain-depressed behavior with many of the strengths described above for pain-depressed unconditioned behaviors (see section II.A.3). These strengths promote assay selectivity. In particular, effective analgesic drugs like morphine attenuate pain-related punishment to increase expression of the target behavior, whereas drugs that produce motor impairment do not produce false-positive analgesia-like effects ([@B191], [@B190]).

Punishment procedures are also associated with several disadvantages, including those mentioned above for pain-depressed unconditioned behaviors (see section II.A.3). Three other weaknesses specific to pain-related punishment of responding will be mentioned here. First, some degree of training is usually required to establish the baseline behavior to be punished, and that behavior must be established in an apparatus suitable for delivery of the noxious stimulus when the response R is emitted. In a related point, punishment procedures work best when the punishing stimulus is delivered with rapid onset and short duration beginning immediately after the designated response, because punishing stimuli have their greatest impact on behaviors that immediately precede stimulus delivery ([@B211]). These temporal parameters are most easily achieved with thermal or mechanical stimuli, or some types of chemical stimuli (e.g., intravenous histamine delivery; [@B255]), that can be delivered with rapid onset and offset. Inflammatory, neuropathic, or disease-related pain stimuli thought to produce spontaneous pain with slower onsets and offsets are more difficult to incorporate directly into punishment procedures; however, hypersensitivity to punishing effects of evocative thermal or mechanical stimuli can be demonstrated in subjects with inflammation, neuropathy, or disease (e.g., [@B191]; [@B207]; [@B74]; [@B47]). Thus, punishment procedures can be used to assess the expression and pharmacological modulation of effects produced by relatively acute external pain stimuli, but they are not useful to assess chronic spontaneous pain.

A second relatively unexplored factor in pain-related punishment of behavior is the impact of the unconditioned or reinforcing consequent stimulus used to maintain behavior and permit detection of punishment. As discussed above, punishment procedures involve a compound consequent stimulus that includes both 1) a reinforcing or unconditioned stimulus sufficient to maintain stable rates of responding in the absence of the noxious stimulus, and 2) a noxious stimulus sufficient to punish baseline rates of responding maintained by the reinforcing/unconditioned stimulus. Previous studies have found that effectiveness of a given punisher depends not only on the intensity of the punisher but also on the effectiveness of the reinforcing stimulus ([@B13]). Moreover, many current studies of pain-related punishment have used food as the positive reinforcing stimulus ([@B191]; [@B110]), but other studies have used qualitatively different stimuli, such as escape from aversive light as a negative reinforcer ([@B150]; [@B84]) or a novel environment as an unconditioned stimulus. The impact of the intensity or type of reinforcing/unconditioned stimulus on pain-related punishment or drug-induced modulation of pain-related punishment has received little attention.

Lastly, an extensive body of literature has found that operant responding punished by aversive electric shock delivery is reversed by anxiolytic drugs (e.g., diazepam) but usually not by analgesic drugs (e.g., morphine) ([@B231]; [@B205]; [@B212]; [@B225]; [@B62]). Although there are important differences between electric shock and more evolutionarily relevant modalities of thermal, mechanical, and chemical noxious stimuli (Corder et al., 2019), these results nonetheless suggest that anxiolytic drugs lacking analgesic effects, such as diazepam, have the potential to produce false-positive analgesic-like effects in procedures that use a noxious stimulus as the punisher. The sensitivity of pain-related punishment to reversal by diazepam or other nonanalgesic anxiolytics remains to be determined.

### 4. Pain Stimulus as a Contextual Stimulus {#s18}

A final strategy for integrating a noxious "pain" stimulus into operant conditioning is in the role of a contextual stimulus as diagrammed here:In this arrangement, operant responding (R) is occasioned by a nonpain discriminative stimulus (S^D^) and reinforced by a nonpain consequent stimulus (S^C^), and performance of this operant response is then evaluated in the context of a putative pain state produced by the pain stimulus (PS). One example of pain-related depression of operant behavior uses an intracranial self-stimulation (ICSS) procedure, in which rats implanted with microelectrodes in a brain reward area are initially trained to press a response lever for pulses of reinforcing electrical brain stimulation ([@B180]; [@B178]; [@B181]). [Figure 9](#F9){ref-type="fig"} shows that increasing frequencies of electrical brain stimulation maintain increasing rates of operant responding and brain-stimulation delivery, and these data can be graphed as a "frequency-rate" curve. Once baseline responding is established, then intraperitoneal injection of dilute acid can serve as one type of noxious stimulus to produce behavioral depression, manifested as rightward and/or downward shifts in frequency-rate curves and decreases in the total number of stimulations delivered across all frequencies. Drugs can then be evaluated for their effectiveness to alleviate acid-induced ICSS depression. For example, [Fig. 10](#F10){ref-type="fig"} shows that acid-induced ICSS depression can be alleviated by morphine doses that do not significantly alter responding in the absence of the acid noxious stimulus ([@B3]), whereas the *κ* agonist nalfurafine was not effective ([@B123]).

![Pain-related depression of ICSS. (A) A photograph of a rat pressing an operant response lever to receive pulses of electrical brain stimulation via a chronically implanted microelectrode connected via a cable to a stimulator outside the frame of the picture. (B) Illustrative baseline data from a frequency-rate ICSS procedure. The *x*-axis shows the frequency of brain stimulation in Hertz available during different components of a behavioral session, and the *y*-axis shows rate of reinforcement normalized as the percent of maximum control rate (%MCR), with MCR defined as the peak rate at any brain-stimulation frequency. Increasing brain-stimulation frequencies maintain increasing rates of reinforcement. (C) Pretreatment with a noxious stimulus (intraperitoneal injection of 1.8% lactic acid) depresses ICSS and shifts the frequency-rate curve to the right, whereas pretreatment with intraperitoneal lactic acid vehicle does not. The number sign (\#) indicates frequencies at which rates after acid were significantly lower than rates after vehicle. (D) Summary data for total ICSS in (C) collapsed across all frequencies of brain stimulation. The *x*-axis shows treatment with lactic acid vehicle (LA Veh) or 1.8% lactic acid (LA). The *y*-axis shows the total number of stimulations expressed as a percentage of noninjection controls. The number sign (\#) indicates depression of ICSS by 1.8% lactic acid. Adapted from [@B178].](pr.118.017210f9){#F9}

![The assay of pain-depressed ICSS can dissociate analgesics from nonanalgesics. (A and B) Effects of the *μ* opioid receptor agonist analgesic morphine (A) and the *κ* opioid receptor agonist nonanalgesic nalfurafine (B) in rats treated with intraperitoneal lactic acid (LA) or with lactic acid vehicle (Veh). Abscissae show the dose in milligrams per kilogram. Ordinates show the percentage of total ICSS reinforcements collapsed across all brain-stimulation frequencies as shown in [Fig. 9D](#F9){ref-type="fig"}. Treatment with lactic acid alone depressed ICSS, whereas vehicle treatment did not. Morphine blocked acid-induced ICSS depression in acid-treated rats at doses that did not affect ICSS in vehicle-treated rats. Conversely, nalfurafine failed to block acid-induced depression of ICSS up to doses that significantly decreased ICSS in vehicle-treated rats. Filled symbols indicate significant differences from LA in (A) or from Veh in (B) (*P* \< 0.05). Data adapted from [@B3] and [@B123].](pr.118.017210f10){#F10}

In addition to improving assay selectivity for effective analgesic drugs, assays of pain-related depression of operant responding have two other strengths. First, baseline levels of operant responding can be maintained by different types of reinforcers (e.g., electrical brain stimulation, food, drug delivery), and reinforcer type can be evaluated as one determinant of pain-related behavioral depression. Second, the arrangement of discriminative stimuli, response requirements, and consequent stimuli in an operant behavioral procedure are defined by the "schedule of reinforcement," and schedule of reinforcement can be manipulated to probe motivational and cognitive processes and evaluate pain- and analgesia-related changes in those processes. Each of these two strengths will be briefly discussed in turn.

With regard to reinforcer type, food delivery is perhaps the easiest type of reinforcer to use in preclinical studies of operant responding, and several studies have reported pain-related and analgesic-reversible depression of food-maintained responding in rats ([@B142]; [@B64]; [@B295]). The example in [Figs. 9](#F9){ref-type="fig"} and [10](#F10){ref-type="fig"} described effects of an acute noxious stimulus (intraperitoneal acid injection) on responding maintained by electrical brain stimulation as a reinforcing stimulus. Although brain stimulation is not a natural reinforcer itself, it functions as a reinforcer by activating the mesolimbic dopamine brain-reward system, which consists of dopamine neurons that originate in the ventral tegmental area of the midbrain and project to forebrain regions that include the nucleus accumbens ([@B82]; [@B181]). The mesolimbic dopamine system is thought to mediate the reinforcing effects of both natural reinforcers and drugs of abuse and also to play a key role in setting mood states along a continuum from euphoria (high dopamine release in target regions such as the nucleus accumbens) to dysphoria (low dopamine release) ([@B129]; [@B187]; [@B17]). Consequently, ICSS procedures offer one strategy to investigate effects of pain stimuli on neural mechanisms of brain reward and mood. Indeed, intraperitoneal acid-induced depression of ICSS correlates with intraperitoneal acid-induced depression of mesolimbic dopamine release, and acid-induced depression of both endpoints can be selectively relieved not only by approved analgesics, but also by candidate analgesics that directly promote dopamine signaling (e.g., the antidepressant and dopamine uptake inhibitor bupropion) ([@B223]; [@B128]; [@B156]).

Drugs constitute another reinforcer type of particular interest in research with pain stimuli, because drug reinforcement in the context of a pain state may provide evidence for analgesic effects ([@B143]). Although pain states decrease operant responding maintained by most reinforcer types, they may increase responding maintained by analgesic drug delivery, presumably because the analgesic relieves the aversive pain state (i.e., "negative reinforcement"). For example, early studies using oral consumption of drugs dissolved in drinking water found that an arthritis model in rats increased consumption of both the NSAID suprofen and the opioid fentanyl ([@B43], [@B44], [@B45]). The increased consumption of suprofen and fentanyl was interpreted as evidence for their increased reinforcing effects due to analgesia in the context of the inflammatory pain state. More recent studies have examined pain-stimulus effects on operant responding maintained by intravenous or intrathecal drug delivery. In one elegant example, rats could press an operant response lever to receive intrathecal injections of the *α*-2 adrenergic agonist clonidine, which has analgesic effects in humans after intrathecal administration ([@B145]). Rats with a spinal nerve ligation model of neuropathy self-administered intrathecal clonidine, whereas sham-lesioned rats did not, and the reinforcing effects of clonidine in the nerve-injured rats were attributed to clonidine's analgesic effects. Another study by this group examined opioid self-administration in nerve-injured rats and found that nerve injury decreased self-administration of low doses of morphine and several other *μ* agonist analgesics; however, self-administration was retained for higher opioid doses that also alleviated mechanical hypersensitivity, and self-administration of these higher doses could be reduced by intrathecal clonidine in nerve-injured rats but not in sham rats ([@B144]). These results were interpreted to suggest that nerve-injury models of neuropathic pain decreased reinforcing effects of low opioid doses and rendered high-dose opioid reinforcement dependent on analgesic effects.

With regard to schedule of reinforcement, assays of operant behavior can be used to evaluate effects of pain stimuli and analgesic drugs on cognitive function ([@B28]; [@B199]; [@B73]; [@B146]). Cognition embraces a range of processes that include attention, perception, working memory, long-term memory, executive function, language, and social cognition, and these different domains of cognitive function can be probed using operant procedures ([@B111]). For example, the relatively basic cognitive process of visual attention can be evaluated using a procedure called the "five-choice serial-reaction time task." In this task, rodents have access to five different nose-poke holes, and a nose-poke response in the correct hole is reinforced by delivery of a food pellet. The identity of the correct hole on any given trial is signaled by a brief light flash in that hole as the discriminative stimulus, and the location of the light flash is systematically varied during experimental sessions. Performance in this task, which depends in part on visual attention to the changing location of the light stimulus, could be impaired by intraperitoneal acid or by paw incision as acute pain stimuli, and these examples of pain-related impairment of performance could be blocked by NSAID and opioid analgesics ([@B146]; [@B220]). Moreover, analgesics were not effective to block impaired attention due to a nonpain stimulus (treatment with the muscarinic acetylcholine receptor antagonist scopolamine).

The disadvantages of studies to examine effects of contextual pain stimuli on operant responding are similar to those described above for studies of pain-depressed unconditioned behaviors (see section II.A.3). In particular, operant responding maintained either by electrical brain stimulation ([@B63], [@B64]; [@B126]) or by food reinforcement ([@B64]; [@B194]) is generally not depressed by either surgical or chemotherapy models of neuropathy despite the presence of mechanical hypersensitivity. These results complement studies of unconditioned behavior (see section II.A.3) in suggesting that preclinical models of putative neuropathic pain fail to produce a full spectrum of pain-related behaviors in laboratory animals and may not be adequate for research on treatments for dimensions of spontaneous pain that involve behavioral depression and functional impairment. An additional weakness is that, as with any operant procedure, some degree of training is required to generate stable behavioral baselines prior to the introduction of pain stimuli and candidate analgesic drugs. However, in contrast to studies of pain-punished behavior (section II.C.3), the pain stimulus does not require rapid onset/offset temporal parameters. Rather, once the operant behavior has been trained, the pain stimulus can be delivered, and the onset, duration, and offset of any changes in behavior can then be tracked. Theoretically, operant responding has the potential to be sensitive to disruption by any persistent spontaneous pain that might be caused by putative chronic-pain stimuli such as surgical- or chemotherapy-induced neuropathy manipulations. However, as noted above, these putative chronic-pain stimuli generally have little effect on operant responding, suggesting that currently available chronic-pain models do not produce sufficient spontaneous pain to depress responding.

### 5. Summary {#s19}

In summary, pain stimuli can serve as a discriminative stimulus, consequent stimulus, or contextual stimulus in operant behavioral procedures. Verbal pain reporting by humans is an operant behavior in which the pain state serves as an interoceptive discriminative stimulus, and pain relief by effective treatment is presumed to serve as one type of reinforcing consequent stimulus that maintains verbal pain reporting. Verbal pain reports are by far the most widely used behaviors in human pain assessment, and as a result, there is some value in seeking to model that behavior using discrimination procedures in laboratory animals. However, the wide use of verbal pain reports in human pain assessment is founded in part on the ease of data collection, and the training and testing of pain discrimination in laboratory animals is much more challenging. Moreover, verbal pain reporting in humans is vulnerable to inaccuracies that compromise both sensitivity and selectivity, and there are increasing efforts to supplement verbal reports with more objective measures of behavior in humans ([@B56]). In particular, behavioral depression and functional impairment are notable and objectively verifiable endpoints important in both the diagnosis and treatment of human pain. These endpoints can be assessed preclinically using procedures that employ pain stimuli as a consequent or contextual stimulus. Ultimately, the integrity of preclinical-to-clinical translational research might benefit more from efforts to investigate expression and treatment of these objective and clinically relevant behaviors, which can readily be studied in both humans and animals, rather than from efforts to develop pain-discrimination procedures in animals.

III. Preclinical Antinociceptive Drug Profiles {#s20}
==============================================

A. The Antinociception Matrix {#s21}
-----------------------------

The variety of "pain-stimulus" independent variables and "pain-behavior" dependent variables provide the foundation for an array of preclinical procedures for assessment of candidate analgesic drugs. [Table 5](#T5){ref-type="table"} shows that this array can be visualized as a matrix, and results for a given drug (e.g., morphine in [Table 5](#T5){ref-type="table"}) can be displayed within this matrix to provide a preclinical antinociception drug (PAD) profile. It is the thesis of this review that PAD profiles will be more useful than results from any single procedure to guide translational research and prioritize candidate analgesics for advancement to clinical studies. Illustrative PAD profiles are provided below for selected drugs, and general recommendations are also provided below for sequencing preclinical studies to generate PAD profiles for other drugs. However, before proceeding to these topics, four caveats warrant mention.

###### 

Preclinical antinociception drug profile for morphine: a positive control

                                 Pain Behavior (Dependent Variable)[*^a^*](#t5n1){ref-type="table-fn"}                                                                                                       
  -------------- --------------- ----------------------------------------------------------------------- --------------- ---------------------------------- ---------------------------------- ---- -------- ------------
  Noxious        Thermal         1--4                                                                                                                                                          10   11, 12   
                 Mechanical      2, 3                                                                                                                                                               13       
                 Chemical        3--5                                                                    6--9            [Table 3](#T3){ref-type="table"}                                                    4, 14, 15
  Inflammation   \+ Thermal      16                                                                                                                                                                 24--26   
                 \+ Mechanical   16--18                                                                                  [Table 3](#T3){ref-type="table"}                                           27       
                 Spontaneous     19, 20                                                                  6, 17, 20--23   [Table 3](#T3){ref-type="table"}   [Table 4](#T4){ref-type="table"}                 21, 28, 29
  Neuropathy     \+ Thermal      30, 31                                                                                                                                                                      
                 \+ Mechanical   30--32                                                                                  [Table 3](#T3){ref-type="table"}                                           13       
                 Spontaneous                                                                             33                                                 [Table 4](#T4){ref-type="table"}                 34

Citations are shown to illustrate effects produced by systemic administration of morphine in preclinical procedures using the designated pain stimulus to produce the designated pain behavior. For this and all other drug profile tables, fill color indicates predominant drug effects as follows: green, drug usually effective; blue, drug effects equivocal; and red, drug usually ineffective. No fill indicates drug not tested. Citations are not intended to be exhaustive, but rather to illustrate typical outcomes.

Numbers correspond to the following references: 1) [@B162]; 2) [@B48]; 3) [@B229]; 4) [@B176]; 5) [@B16]; 6) [@B183]; 7) [@B157]; 8) [@B249]; 9) [@B149]; 10) [@B258]; 11) [@B268]; 12) [@B110]; 13) [@B84]; 14) [@B3]; 15) [@B146]; 16) [@B83]; 17) [@B41]; 18) [@B119]; 19) [@B244]; 20) [@B88]; 21) [@B142]; 22) [@B226]; 23) [@B107]; 24) [@B191]; 25) [@B189]; 26) [@B18]; 27) [@B221]; 28) [@B64]; 29) [@B220]; 30) [@B175]; 31) [@B61]; 32) [@B265]; 33) [@B282]; and 34) [@B127].

First, the antinociception matrix provides a framework for consolidating and displaying data from a broad range of preclinical experiments. The matrix has two major dimensions, with rows for major classes of pain stimuli (as shown in [Table 1](#T1){ref-type="table"}; disease models excluded for simplification) and columns for major classes of pain behavior (as shown in [Table 2](#T2){ref-type="table"} and discussed in detail in section II). Each cell within the matrix represents a family of procedures using the designated class of pain stimuli to generate the designated class of pain behaviors; however, further subcategories of different pain stimuli and pain behaviors clearly exist and may be relevant for certain applications. For example, the pain-stimulus category for neuropathy (bottom three rows in the matrix) as shown here consolidates results using both surgical and chemotherapy models, but there may be occasions when it is relevant to distinguish between these models. Similarly, the pain-behavior category for contextual pain-stimulus effects on operant behavior (far-right column, PS→\[S^D^→R→S^C^\]) consolidates results using all schedules of reinforcement; however, different schedules of reinforcement can be used to assess different motivational and cognitive processes, and again, there may be occasions when it is relevant to distinguish between these models.

Second, the matrix also includes a third dimension using color to show drug effectiveness in the family of procedures represented by each cell. In the convention used here, green indicates that the drug is usually effective, red indicates that the drug is usually ineffective, blue indicates a pattern of mixed or ambiguous results, and white indicates that the drug has not been tested. References to support the color assignment are listed within the cell. This convention is intended to facilitate use of the matrix to compare drug effects across procedures, but with only three levels of effectiveness (effective, mixed, ineffective), the designated effect level has low resolution. Moreover, the quality or consistency of evidence leading to a summary of effectiveness may vary across studies. Future meta-analytic strategies could be developed to provide more quantitative and continuous summaries of drug effectiveness within each cell.

A third caveat to this matrix is that it does not include dimensions for other variables that may be of interest, such as the route of drug administration or the sex, strain, species, or age of the experimental subject. These types of variables could be incorporated by, for example, juxtaposing the PAD profiles for a given drug after systemic versus intrathecal administration or in male versus female subjects.

A final caveat is that procedures have yet to be developed for many cells in the matrix. Morphine is almost always used as a positive control during assay development because it is the prototype compound from a drug class (*μ* opioid receptor agonists) that is well established to produce clinically effective analgesia across a wide range of pain states. Accordingly, blank cells in the PAD profile for morphine in [Table 5](#T5){ref-type="table"} indicate that procedures for these cells have yet to be developed. In some cases, development of new procedures may not be feasible or warranted. For example, existing neuropathic pain stimuli do not produce reliable signs of spontaneous pain-stimulated unconditioned behaviors (e.g., grimacing; [@B122]), and as a result, there are no established models for drug effects on neuropathy-associated spontaneous unconditioned behaviors (row 9, column 1). Additionally, it was argued in section II.C.2 that development of preclinical "pain-discrimination" procedures may not be warranted even though operant discrimination behavior in the form of verbal reporting is the most commonly used outcome in assessment of human pain. In other cases, however, development of new procedures might be helpful. For example, there are currently no procedures to assess drug effectiveness to relieve inflammation + thermal stimulus--induced depression of unconditioned behavior (row 4, column 2). Such procedures might be useful to complement assays of inflammation-associated hypersensitivity of thermal stimulus--induced withdrawal reflexes. A possible and relatively simple procedure to represent this cell could be assessment of food consumption on a hot plate heated to a threshold temperature (e.g., 42°C) in rats or mice treated with intraplantar CFA. A predicted outcome is that thermal stimulation would reduce food consumption in CFA-treated subjects, and that morphine would dose-dependently block/reverse this effect. More generally, there is a research opportunity to develop new procedures for some cells in the matrix.

B. *μ* Opioid Receptor Agonists: A Representative Positive Control {#s22}
------------------------------------------------------------------

With these caveats in mind, we can now turn to the PAD profile for morphine as a representative positive control. References cited within each cell in [Table 5](#T5){ref-type="table"} include studies discussed above in section II, and most cells also include a few additional citations to illustrate both the types of procedures representative for a given cell and the effects of systemically administered morphine within those procedures.

As indicated by the predominance of green cells in [Table 5](#T5){ref-type="table"}, morphine is effective in most preclinical antinociception assays. This is not surprising given that morphine is a clinically effective analgesic often used as a positive control to validate new procedures, and procedures that fail to show effectiveness of morphine are generally considered to be of limited use for evaluating other candidate analgesics. The first column in the matrix (PS→UR) shows morphine effects on pain-stimulated unconditioned behaviors that make up the majority of all preclinical research, and many more references could be cited to support effectiveness of morphine and other *μ* opioid receptor agonists in these procedures. Fewer studies have been conducted to assess effects of morphine and other *μ* agonists on other types of pain-related behaviors; however, morphine is also generally effective to alleviate pain-depressed unconditioned behaviors (column 2: PS→\[US→UR\]), pain-punished operant behavior (column 6: S^D^→R→PS), and pain-depressed operant behavior (column 7: PS→\[S^D^→R→S^C^\]). Notably, morphine and other *μ* agonists typically have inverted-U shaped dose-effect curves in these procedures, with peak antinociception produced by relatively low doses, whereas higher doses produce sedation and motor impairment that obscure antinociception. Morphine also reliably alleviates pain-related conditioned place aversion (column 3: CS+US; CS→CR), and in the only published pain-discrimination study, it blocked the discriminative stimulus effects of noxious heat (column 5: PS→R→S^C^).

There are two exceptions to the general antinociceptive effectiveness of morphine in [Table 5](#T5){ref-type="table"}. In the first exception (row 2, column 6; reference 13), morphine was tested in an operant-escape apparatus consisting of an illuminated start box connected by a runway to a dark goal box ([@B84]). Features of the apparatus served as the discriminative stimulus S^D^, locomotion down the runway to the goal box served as the response R, and escape from the presumably aversive light served as the reinforcing consequent stimulus S^C^. Locomotion down the runway could be punished by elevation of probes in the runway floor to deliver a punctate mechanical stimulus to subjects' feet as an additional consequent stimulus S^C^, such that probe elevation decreased latency to leave the start box. In rats with a chronic-constriction nerve-injury model of neuropathy, relatively low probe heights were sufficient to punish behavior, and morphine was effective to block this hypersensitivity to probe punishment, such that subjects left the start box more quickly after morphine treatment (row 8, column 6). The procedure has been further validated for evaluation of candidate analgesics in subjects with other types of inflammation- or neuropathy-induced mechanical hypersensitivity ([@B234]). However, in control uninjured rats, higher probe elevations were required to punish behavior, and morphine failed to block punishment produced by these higher probe elevations (row 2, column 6). These results could be interpreted to suggest that either 1) punishment by higher probe elevations reflected a nonpain effect, such as physical obstruction of the runway path, that could not be attenuated by morphine, or 2) morphine failed to reduce sensitivity to the noxious stimulus produced by stepping on these higher probes, just as it also fails to block punishment by electric shock as discussed above ([@B231]; [@B205]; [@B212]; [@B225]; [@B62]). Regardless of the interpretation, these results suggest limited utility of the procedure to detect mechanical antinociception in uninjured subjects.

The equivocal data from conditioned place-preference studies (column 4: PS→\[CS+US; CS→CR\]) serve as an intriguing second exception to the general antinociceptive effectiveness of morphine. As summarized in [Table 4](#T4){ref-type="table"}, many early studies found that pain states blocked or attenuated morphine-induced place preferences, but these studies were not designed to test the hypothesis that morphine-induced pain relief would produce rewarding effects leading to a place preference. Rather, these studies were conducted to test the different hypothesis that pain states would attenuate opioid reward, and results supporting this hypothesis were deemed worthy of publishing by both authors and journals. The use of place conditioning to evaluate putative pain relief was not popularized until later, and these later studies hypothesized a different effect of pain states on morphine reward (i.e., that morphine analgesia in the context of a pain state would enhance the potency or effectiveness of morphine reward). Again, studies that supported the hypothesis were deemed worthy of publication by authors and journals. In both cases, the published articles supported the prevailing hypotheses, but the conflicting hypotheses seem to have generated conflicting results. It remains possible that these conflicting results reflect subtle differences in experimental parameters, but the fact that similar experimental designs have generated distinct results aligned more with their hypotheses than their methodology suggests the influence of publication bias ([@B6]). At the very least, these results suggest caution in the use of place-preference procedures to examine putative rewarding effects of pain relief by candidate analgesics.

C. *κ* Opioid Receptor Agonists: A Representative Negative Control {#s23}
------------------------------------------------------------------

In the course of translational research on analgesic development, "false-positive" drugs will be identified that appear to have therapeutic potential based on preclinical findings but that ultimately fail to function as analgesics in humans. Apparent clinical failure can result not only from lack of efficacy but also from dose-limiting safety concerns, species differences in the drug target, or poorly designed clinical trials, and characterization of a given drug as a false positive should be made with appropriate caution. Nonetheless, once identified and generally accepted by the field, false positives for a given pain indication can serve as valuable tools for use in refining preclinical research strategies. Specifically, false positives identify vulnerabilities in the existing research platform that allowed the drug to advance in the first place, and more importantly, they can be back-translated into preclinical research as part of an iterative process to develop new and more selective preclinical procedures ([Fig. 1](#F1){ref-type="fig"}).

In this review, centrally acting *κ* opioid receptor agonists have been used as a representative class of negative controls that has uniformly failed in the clinic due to inadequate effectiveness, unacceptable side effects, or both ([@B200]; [@B123]). [Table 6](#T6){ref-type="table"} shows the PAD profile for a range of systemically administered *κ* agonists in preclinical studies. Like morphine and other *μ* agonists, *κ* agonists generally produce analgesic-like effects in conventional assays of pain-stimulated behaviors evoked by a wide range of different pain stimuli. These analgesic-like effects, coupled with evidence for low abuse liability, have been major factors in decisions to advance *κ* agonists as candidate analgesics ([@B155]; [@B39]). However, [Table 6](#T6){ref-type="table"} also shows that *κ* agonists, unlike morphine, have failed to produce analgesic-like effects in all other categories of pain behaviors for which they have been tested. These results provide one source of evidence to suggest that drug effects may vary across different pain behaviors even when those behaviors are produced by the same pain stimulus. These results further suggest that inclusion of procedures to evaluate these other pain behaviors can improve the selectivity and predictive validity of preclinical analgesic testing. Lastly, it is also clear from [Table 6](#T6){ref-type="table"} that *κ* agonists have been tested less thoroughly than morphine and other *μ* agonists in assays of pain-depressed unconditioned behavior, or in assays incorporating pain stimuli in Classical- or operant-conditioning procedures. These sparsely filled or empty cells provide opportunities for new research that might identify niche conditions under which *κ* agonists might be effective.

###### 

Preclinical antinociception drug profile for *κ* opioid receptor agonists: a negative control

                                 Pain Behavior (Dependent Variable)[*^a^*](#t6n1){ref-type="table-fn"}                          
  -------------- --------------- ----------------------------------------------------------------------- ------ --- ---- -- --- -----------
  Noxious        Thermal         1--4                                                                                           
                 Mechanical      1--3, 5                                                                                        
                 Chemical        1--3, 6, 7                                                              8, 9   6   10          7, 11--13
  Inflammation   \+ Thermal      8, 9, 14, 15                                                                               9   
                 \+ Mechanical   15, 16                                                                                         
                 Spontaneous                                                                             8                      
  Neuropathy     \+ Thermal      17--20                                                                                         
                 \+ Mechanical   19, 20                                                                                         
                 Spontaneous                                                                             20                     

Citations are shown to indicate effects produced by systemic administration of centrally acting and pharmacologically selective *κ* opioid receptor agonists (U50,488, U69,593, enadoline, nalfurafine, GR89696) in different types of preclinical procedures using the designated pain stimulus to produce the designated pain behavior. Fill color indicates predominant drug effects: green, drug usually effective; and red, drug usually ineffective. No fill indicates drug not tested. Citations are not intended to be exhaustive, but rather to illustrate typical outcomes.

Numbers correspond to the following references: 1) [@B229]; 2) [@B58]; 3) [@B94]; 4) [@B20]; 5) [@B21]; 6) [@B16]; 7) [@B182]; 8) [@B183]; 9) [@B190]; 10) [@B237]; 11) [@B184]; 12) [@B123]; 13) [@B32]; 14) [@B134]; 15) [@B69]; 16) [@B60]; 17) [@B288]; 18) [@B227]; 19) [@B245]; and 20) [@B282].

The *κ* agonist nalfurafine provides an especially instructive case study in failed analgesic drug development. Nalfurafine was initially developed as a candidate analgesic that produced antinociception in multiple assays of noxious, inflammatory, and neuropathic pain-stimulated behavior in mice, rats, and nonhuman primates ([@B169]; [@B58], [@B60], [@B59]). Ultimately, nalfurafine was approved for clinical use in Japan, and it remains the only selective *κ* agonist available for any clinical indication anywhere in the world; however, it was approved for the treatment of itch, not pain ([@B98]). Despite the promising preclinical results from conventional assays of pain-stimulated behaviors, no public results are available from any clinical trials with nalfurafine as a candidate analgesic, and there is no indication that nalfurafine is used off-label for treatment of pain. Thus, it appears that nalfurafine is similar to other centrally acting *κ* agonists in being clinically untenable for pain treatment due to poor effectiveness and/or unacceptable side effects. In the only preclinical study consistent with its clinical failure, nalfurafine failed to produce a morphine-like blockade of intraperitoneal acid-induced ICSS depression in rats (an assay of pain-related depression of operant behavior, reference 12 in [Table 6](#T6){ref-type="table"}) ([@B123]).

Although centrally acting *κ* agonists have not succeeded as candidate analgesics, *κ* agonists with different pharmacodynamic or pharmacokinetic attributes continue to be developed, and novel approaches to preclinical drug assessment can play a role in evaluating new generations of *κ* agonists. As one example, drugs can display pharmacodynamic bias in their efficacy and potency to activate different receptor-coupled signaling pathways, and *κ* receptor ligands with bias to activate G-protein versus *ß*-arrestin signaling pathways have emerged as one class of candidate analgesics that might retain *κ* receptor--mediated antinociceptive effects while reducing undesirable side effects ([@B112]; [@B217]). In support of this possibility, one recent study found that the G protein--biased *κ* agonist triazole 1.1 produced significant antinociception not only in conventional preclinical assays of pain-stimulated behavior but also in an assay of pain-related ICSS depression ([@B32]).

As another example, a class of *κ* agonists is being developed with the goal of limiting pharmacokinetic distribution across the blood-brain barrier ([@B266]; [@B264]; [@B91]; [@B103]). After systemic administration, these compounds are restricted largely to the periphery, where they can act on peripheral *κ* receptors, but they distribute poorly to the central nervous system and to *κ* receptor populations in the brain and spinal cord. The working hypothesis with these compounds is that activation of peripheral *κ* receptors, such as those located on primary nociceptor terminals, will be sufficient to produce clinically meaningful analgesia, and restricted distribution to brain will minimize centrally mediated side effects such as dysphoria and sedation. Peripherally selective *κ* agonists produce antinociception in a broad range of preclinical procedures using pain-stimulated unconditioned behaviors; however, early generation peripherally selective *κ* agonists failed to block intraperitoneal acid-induced depression of ICSS in rats ([@B184]). Although some compounds in this class have advanced to clinical trials, none have been approved for clinical use ([@B135]; [@B8]; [@B272]).

D. Cannabinoid Receptor Agonists: A Representative Class of Candidate Analgesics {#s24}
--------------------------------------------------------------------------------

Medical marijuana is one of the most prominent and controversial treatments to have emerged during the last 2 decades for the treatment of pain ([@B171]; [@B222]; [@B263]). U.S. federal law continues to classify marijuana as a Schedule I drug with no approved clinical indications, but marijuana has been legalized for recreational and/or medical use in more than 30 states and the District of Columbia. Moreover, despite weak evidence for clinical effectiveness as an analgesic (see below), pain is the most frequently endorsed reason for medical marijuana use in the United States and in other countries ([@B203]). The primary psychoactive constituent in marijuana is A9-tetrahydrocannabinol (THC), which acts as a low-efficacy agonist at cannabinoid 1 and cannabinoid 2 receptors, and many synthetic cannabinoid receptor agonists have also been developed as both experimental drugs and as candidate therapeutics for purposes that include pain management ([@B54]; [@B55]). [Table 7](#T7){ref-type="table"} shows the PAD profile for THC and several other pharmacologically similar drugs that function as agonists at cannabinoid 1 and cannabinoid 2 receptors (CP55940, WIN55212-2, nabilone) (for comprehensive reviews, see [@B141]; [@B55]).

###### 

Preclinical antinociception drug profile for cannabinoid receptor agonists: a class of candidate analgesics

                                 Pain Behavior (Dependent Variable)[*^a^*](#t7n1){ref-type="table-fn"}                        
  -------------- --------------- ----------------------------------------------------------------------- ------ -- -- -- ---- ----
  Noxious        Thermal         1--3                                                                                    8    
                 Mechanical      1, 2, 4                                                                                      
                 Chemical        1, 5, 6                                                                 6, 7                 6
  Inflammation   \+ Thermal      9--11                                                                                        
                 \+ Mechanical   1, 4, 9                                                                                      
                 Spontaneous                                                                             12                   
  Neuropathy     \+ Thermal      13--15                                                                                       
                 \+ Mechanical   14--16                                                                                  18   
                 Spontaneous                                                                             17                   16

Citations are shown to indicate effects produced by systemic administration of cannabinoid receptor agonists \[∆9-tetrahydrocannabinol, 2-\[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl\]-5-(2-methyloctan-2-yl)phenol (CP55940), (11*R*)-2-methyl-11-\[(morpholin-4-yl)methyl\]-3-(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo\[6.3.1.0^4^,^12^\]dodeca-2,4(12),5,7-tetraene (WIN55212-2), nabilone\] in different types of preclinical procedures using the designated pain stimulus to produce the designated pain behavior. Fill color indicates predominant drug effects: green, drug usually effective; and red, drug usually ineffective. No fill indicates drug not tested. Citations are not intended to be exhaustive, but rather to illustrate typical outcomes.

Numbers correspond to the following references: 1) [@B243]; 2) [@B260]; 3) [@B66]; 4) [@B242]; 5) [@B165]; 6) [@B120]; 7) [@B158]; 8) [@B110]; 9) [@B131]; 10) [@B115]; 11) [@B46]; 12) [@B108]; 13) [@B139]; 14) [@B30]; 15) [@B204]; 16) [@B127]; 17) [@B282]; and 18) [@B207].

Three inferences can be drawn from this profile. First, THC and the other cannabinoid receptor agonists have been tested most extensively in assays of pain-stimulated unconditioned behaviors (column 1, PS→UR). [Table 7](#T7){ref-type="table"} shows illustrative citations for each cell in this category, and many more studies could be cited to make the same points ([@B54]; [@B55]). Overall, like both morphine (the positive control) and *κ* opioid agonists (the negative control), THC and the other cannabinoid receptor agonists are reliably effective in all types of pain-stimulated unconditioned behaviors.

Second, THC and other cannabinoid receptor agonists have been tested only sparingly in procedures with other types of behavioral endpoints, and in most of those studies, cannabinoid agonists have failed to produce antinociception. Thus, these cannabinoids have failed to alleviate intraperitoneal acid-induced depression of wheel running in mice ([@B158]), intraperitoneal acid-induced depression of feeding and ICSS in rats ([@B120]), noxious heat-induced punishment of food-maintained responding in squirrel monkeys ([@B110]), punishment of time spent in a place associated with mechanical paw stimulation in rats with chronic-constriction nerve injury ([@B207]), or formalin-induced depression of ICSS in rats ([@B127]). In the two exceptions to this general finding, THC did alleviate depression of wheel running produced in female rats by application of allyl isothiocyanate to the dura (a model of migraine pain; [@B108]), and CP55940 alleviated depression of marble burying produced in male mice by chronic-constriction injury to the sciatic nerve ([@B282]). Cannabinoids have not yet been evaluated at all in assays of Classical conditioning with pain stimuli. There is significant opportunity for further research to examine effects of THC and other cannabinoids on pain-related behaviors other than conventional pain-stimulated unconditioned behaviors.

Lastly, it would appear that inclusion of these other behavioral endpoints could improve preclinical-to-clinical translation of results with cannabinoids. The uniformly robust effects of THC and other cannabinoid receptor agonists in all assays of pain-stimulated unconditioned behavior are clearly at odds with the weak, absent, or even hyperalgesic effects of cannabinoid agonists and cannabis products in humans evaluated for verbal pain reports elicited by acute exposure either to noxious experimental stimuli or to acute inflammatory stimuli such as postsurgical pain ([@B215]; [@B80]; [@B273]; [@B118]). Cannabinoids are generally thought to have their best therapeutic effectiveness for treatment of chronic pain, including neuropathic pain; however, even here, a growing body of evidence from clinical trials suggests that THC and cannabis products have weak and unreliable analgesic effectiveness despite being tested up to doses that produce problematic side effects ([@B70]; [@B12]; [@B166]; [@B252]). Thus, results from clinical studies appear to align more closely to preclinical results from assays of pain-depressed and pain-punished behaviors than to results from assays of pain-stimulated unconditioned behaviors. More extensive testing of cannabinoids on a broader range of pain-related behaviors may help to clarify the circumstances under which cannabinoids are most likely to be effective.

E. Recommendations for Preclinical Testing {#s25}
------------------------------------------

The antinociception matrix in [Tables 5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, and [7](#T7){ref-type="table"} serves as a map of the preclinical experimental space within which pain-related behaviors are expressed and candidate analgesics are tested. Any given study will explore a subset of domains within the map, and over time, data for a given drug or drug class can accumulate to generate increasingly comprehensive topographies. Moreover, because the principles of unconditioned, classically conditioned, and operant conditioned behavior apply to humans as well as to laboratory animals, this same matrix could be used to organize and display results from human laboratory studies and clinical trials, and a comparison of PAD profiles for a given drug or drug class in animals and humans could serve as a tool to guide translational research. However, as with the exploration of a physical space, the progress of research through this experimental space must begin somewhere and pursue a path intended to reveal the most salient features of the terrain. At present, the most common path pursued by academic and industry laboratories is to work vertically down the first column of the antinociception matrix by evaluating drug effects on pain-stimulated unconditioned behaviors elicited by representative noxious, inflammatory, and neuropathic pain stimuli. This path has proved to be inefficient. It will now be argued that a better path is available that features a horizontal track of research across pain behaviors.

The prioritization of preclinical procedures into a path for initial drug testing should accommodate factors that include the physiologic relevance of the pain stimuli and pain behaviors to human pain states, the complementary strengths and weaknesses of the outcome measures with regard to assay sensitivity and selectivity, and the amenability of the path to high throughput. [Figure 11](#F11){ref-type="fig"} shows one path that might be useful in achieving these goals in analgesic development for treating acute inflammatory pain (e.g., postsurgical pain). This strategy relies on three procedures: 1) intraperitoneal acid-stimulated stretching (a pain-stimulated unconditioned behavior), 2) intraperitoneal acid-depressed nesting (a pain-depressed unconditioned behavior), and 3) control nesting in the absence of the pain stimulus (a measure of nonselective drug effects on behavior).

![Proposed path for initial testing with a candidate analgesic for acute inflammatory pain. One strategy for initial drug screening is to evaluate the drug potency, efficacy, and time course in mice using three assays: 1) intraperitoneal acid-stimulated stretching, 2) intraperitoneal acid-depressed nesting, and 3) control nesting in the absence of the noxious stimulus. Analgesia is indicated if a drug shows similar potency/effectiveness to block acid-induced stimulation of stretching and depression of nesting but has lower potency/effectiveness to impair control nesting (acid stretch = acid nest \> control nest). This type of drug would be considered "high priority" for further testing. Conversely, analgesia is less likely if a drug shows similar potency/effectiveness to decrease acid-stimulated stretching and control nesting and has lower potency/effectiveness to block acid-induced depression of nesting (acid stretch = control nest \> acid nest). Such a drug likely produces motor impairment with or without analgesia, and such a drug would be considered "low priority" for further testing. Lastly, analgesia is not indicated if a drug decreases control nesting but fails to produce antinociception in the assays of either acid-stimulated stretching or acid-induced depression of nesting (control nest \> acid stretch and acid nest). Such a drug could be rejected from further testing.](pr.118.017210f11){#F11}

Intraperitoneal acid is physiologically relevant as a pain stimulus insofar as inflamed tissue is often acidic relative to nondamaged tissue, and protons activate ion channels (e.g., transient receptor potential V1 and acid-sensing ion channels) expressed on primary nociceptors ([@B50]; [@B29]; [@B93]). As described above, intraperitoneal acid-stimulated stretching and depression of nesting are useful as complementary outcome measures because of their complementary strengths and weaknesses. Intraperitoneal acid-stimulated stretching is notable for its sensitivity to the principal classes of clinically effective analgesics in the treatment of inflammatory pain (*μ* opioid receptor agonists, NSAIDs), and this type of assay is also useful for rapid assessment of drug potency, efficacy, and time course to guide drug dosing and temporal parameters in other studies. However, as in all assays of pain-stimulated unconditioned behaviors, intraperitoneal acid-stimulated stretching can be reduced by nonselective behavioral effects such as sedation or motor impairment, and as a result, these assays lack selectivity to analgesic drugs and are extremely vulnerable to false-positive drug effects. Intraperitoneal acid-induced depression of nesting, by contrast, can compensate for this weakness by virtue of its selectivity. It is also sensitive to *μ* agonists and NSAIDs, but existing data suggest that drugs that produce nonselective behavioral disruption do not produce false-positive analgesic-like effects; rather, such drugs only exacerbate acid-induced depression of nesting. Moreover, assays of pain-depressed unconditioned behaviors benefit from homology to pain-related behavioral depression and functional impairment as cardinal signs in human pain assessment. Taken together, these two procedures (intraperitoneal acid-induced stimulation of stretching and depression of nesting) constitute a horizontally organized set of cells in the antinociception matrix (row 3, columns 1 and 2). Evaluation of drug effects on these two pain behaviors can be further complemented by evaluation of drug effects on control nesting in the absence of the noxious stimulus to provide a direct measure of drug potency and effectiveness to disrupt general behavior as an undesirable side effect.

This trio of procedures is amenable to relatively high throughput. With regard to the independent variable, intraperitoneal acid is advantageous as a pain stimulus because it is easily quantified and delivered, produces a robust array of pain behaviors with a rapid onset and relative short duration of action (∼1 hour), and can be administered repeatedly to the same subject if needed for within-subject experimental designs or repeated dosing experiments. With regard to the dependent variables, stretching and nesting are unconditioned behaviors that require no training and can be quantitatively assessed as ratio variables amenable to parametric statistics. Moreover, these variables can be assessed with relatively little specialized equipment. Stretching requires only a clear chamber to permit observation, and although that observation can be performed in real time by an observer, it is best recorded by a video camera to minimize experimenter interactions with subjects during testing. These videos can then be scored later by blinded observers. Nesting requires only individually housed subjects and can be assessed in each subject's home cage using nesting material commonly provided to mice as part of standard husbandry practices. Photographs of the cage floor at the end of each session can again be scored by blinded observers.

Once drug effects in these three procedures are determined, they can then be compared to prioritize drugs for further testing. Analgesia is indicated if a drug blocks both acid-induced stimulation of stretching and depression of nesting with similar potencies, and has weaker potency or effectiveness to impair control nesting (acid stretching = acid nesting \> control nesting). Such a drug could then be prioritized for further testing to determine mechanisms of action, effects of chronic treatment, or effects in other procedures using other pain stimuli or pain behaviors. Conversely, analgesia is less likely if a drug decreases both acid-stimulated stretching and control nesting with similar potencies but fails to block acid-induced depression of nesting (acid stretching = control nesting \> acid nesting). This type of profile could be produced by a drug that produces both analgesic effects and motor impairment at similar doses, but this profile could also reflect drug-induced motor impairment without analgesia. These possibilities could be dissociated using follow-up approaches (e.g., place-conditioning procedures); however, further testing with such a drug would likely have lower priority, because even if the drug did have analgesic effects, motor impairment might be expected as a dose-limiting side effect that could impede delivery of analgesic doses. Lastly, a drug that was ineffective in assays of both acid-stimulated stretching and acid-induced depression of nesting up to doses that impaired control nesting would have the lowest potential as an analgesic and the lowest priority for further testing (control nesting \> acid stretching and acid nesting).

It should be emphasized that this is only one of many possible strategies that could be developed for more efficient use of preclinical procedures for assessment of candidate analgesics. The approach described above focuses on the use of an acute noxious stimulus to model pain states associated with the tissue-acidosis component of acute injury and inflammation, and drugs identified with this approach might serve as useful alternatives to *μ* opioid agonists and NSAIDs for treatment of acute inflammatory pain. This is not trivial. For example, the National Institutes of Health recently announced a major research initiative that seeks to enhance pain management by discovering new nonaddictive analgesics that could replace highly addictive opioid analgesics (<https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative>). Although opioids are used to treat a wide range of pain conditions, one major use is for relatively short-term pain states related to injury and inflammation, such as postsurgical pain. As a result, the discovery of new analgesics to treat short-term pain states could enable a sizeable reduction in prescription opioid use.

Nonetheless, analgesic discovery for more chronic inflammation-, neuropathy-, or disease-related pain states is also critical, and analgesic development for these chronic pain states would also benefit from improved preclinical research strategies that capitalize on a horizontal path through the matrix. The most widely used endpoints in preclinical research on chronic pain are measures of hypersensitive withdrawal responses from mechanical or thermal stimuli. Procedures that rely on these pain-stimulated unconditioned behaviors generally have the strengths and weaknesses of other "sensitive" preclinical procedures (see section II.A.2), but these procedures can be complemented by potentially more selective procedures that assess hypersensitivity to behavioral depression or punishment by these same mechanical and thermal stimuli (sections II.A.3, II.C.3, and II.C.4). For example, several studies have compared treatment effects on hypersensitive paw withdrawal (a pain-stimulated behavior) and place escape/avoidance (a pain-punished behavior) elicited by acute mechanical or thermal stimuli in subjects with surgical neuropathy manipulations ([@B121]; [@B207]; [@B47]). Morphine generally reduces both types of pain behavior, and intriguingly, some treatments relieve pain-punished behaviors without affecting hypersensitive withdrawal responses (e.g., duloxetine; [@B207]). Although such findings could reflect anxiolysis or learning impairment (see section II.C.3), they are often interpreted to suggest that the treatment under consideration blocks "affective" versus "sensory" dimensions of pain; however, the translational implications of such findings remain to be determined. For example, it is not yet clear whether drugs that relieve pain-punished behaviors without relieving hypersensitive withdrawal responses should be prioritized for advancement to clinical testing.

The sequential use of procedures that assess drug effects on hypersensitive pain-stimulated and pain-punished behaviors is also associated with two other significant challenges. First, this approach relies on measures of hypersensitive responses to acutely applied external stimuli, but clinically relevant chronic pain in humans more often manifests as spontaneous pain that is independent of external stimuli and sufficient to impair function and quality of life ([@B15]; [@B56]). Different approaches will be required for preclinical assessment of the expression and treatment of chronic spontaneous pain, but as reviewed above, current experimental manipulations for producing putative chronic pain in rodents often produce little or no evidence of impaired function as sign of spontaneous pain. As a result, these procedures provide little opportunity either to validate the existence of chronic spontaneous pain or to investigate effects of candidate analgesics on functional impairment that might be caused by chronic spontaneous pain. No doubt, there will be continued efforts to develop methods for sensitive detection of chronic pain-associated functional impairment. At present, conditioned place-preference procedures appear to lay the strongest claim to usefulness for assessment of chronic spontaneous pain, and these CPP procedures have the strengths and weaknesses described above in section II.B.3.

A second challenge is the lack of robust positive controls or consensus negative controls that can be used to validate preclinical procedures for chronic pain. For example, gabapentin is often used clinically to treat various types of neuropathic pain, but prevailing clinical data suggest that it has limited clinical effectiveness both in absolute terms and in comparison with other analgesics such *μ* opioid receptor agonists or monoamine uptake inhibitor antidepressants ([@B198]; [@B70]; [@B281]). Despite its marginal clinical effectiveness, gabapentin is often used to validate sensitivity of preclinical assays of neuropathic pain, and it often produces antinociception indistinguishable in magnitude either from effects of other positive controls known to be more effective clinically or from the maximum possible effect attainable in the procedure ([@B202]; [@B239]; [@B282]). Presumably, one goal of analgesic development for neuropathic pain is to improve on existing but imperfect compounds like gabapentin; but to accomplish this task, it will be necessary to use procedures capable of detecting such improvement. Despite these caveats, the general recommendation applies that analgesic testing for any type of pain state will benefit from use of multiple pain behaviors that have complementary strengths and weaknesses. Moreover, as drugs advance to clinical testing, both effective and ineffective drugs can be back-translated as positive and negative controls to refine the preclinical testing strategy and improve both sensitivity and selectivity in analgesic drug discovery ([Fig. 1](#F1){ref-type="fig"}).

IV. Other Considerations {#s26}
========================

A. Analgesic Tolerance {#s27}
----------------------

Analgesics are often administered repeatedly for periods of days, months, or even years to treat sustained pain states, and analgesic tolerance is a potential barrier to effective pain management ([@B99]). The expression and mechanisms of tolerance, and especially opioid tolerance, have been extensively studied in preclinical research by evaluating changes in drug-induced antinociception during regimens of repeated drug treatment ([@B45]; [@B267]; [@B294]; [@B1]). Tolerance to the antinociceptive effects of *μ* opioid agonists like morphine is a robust preclinical phenomenon, many different mechanisms of opioid antinociceptive tolerance have been identified, and this mechanistic research has led to proposals of many different strategies to reduce opioid analgesic tolerance in humans. However, this preclinical research has relied almost exclusively on assays of pain-stimulated unconditioned behaviors, and none of this research has led to approved treatments to mitigate opioid analgesic tolerance in clinical settings. Consequently, research on opioid antinociceptive/analgesic tolerance represents another area of largely failed preclinical-to-clinical translation.

The narrow preclinical focus on pain-stimulated unconditioned behaviors may contribute to this poor translation of results. This review has emphasized the point that preclinical pain stimuli produce a range of different pain behaviors that can be differentially modified by acute drug treatments, and this principle also applies to the potential for differential expression and mechanisms of antinociceptive tolerance to repeated drug treatment. For example, one study compared the development of antinociceptive tolerance produced by a regimen of repeated morphine treatment in rats tested for a pain-stimulated unconditioned behavior (intraperitoneal acid-induced stimulation of stretching) and a pain-depressed operant behavior (intraperitoneal acid-induced depression of ICSS) ([@B2]). Complete tolerance developed to morphine antinociception in the assay of intraperitoneal acid-stimulated stretching, but morphine remained effective to alleviate intraperitoneal acid-induced depression of ICSS. Thus, morphine antinociception in the assay of pain-depressed operant behavior was resistant to tolerance. This agrees with the clinical observation that many patients with chronic pain can be maintained on stable opioid doses for long periods, and that dose escalation when it occurs often reflects disease progression and increased pain rather that decreased opioid analgesic effectiveness due to pharmacodynamic tolerance ([@B71]). Indeed, tolerance to opioid-induced side effects like sedation and nausea/emesis often facilitates the use of opioids for pain treatment ([@B38]). Overall there is a clear opportunity for research on the expression and mechanisms of opioid antinociceptive tolerance in assays using outcome measures other than pain-stimulated unconditioned behaviors. Moreover, Classical- and operant-conditioning factors that influence pain expression can also influence tolerance to analgesic effects of drugs ([@B238]), and the interaction between pain states, drug tolerance, and conditioning is largely unexplored.

B. Safety {#s28}
---------

An important consideration in any analgesic development program is the discovery of drugs that are safe as well as effective. Safety assessments rely on a multitude of outcome measures concerned with drug effects on multiple physiologic and behavioral endpoints; however, novel behavioral measures that can be used to assess antinociception can also be used to provide one source of useful information on drug safety. Assays of pain-depressed unconditioned behavior, pain-punished operant behavior, and pain-depressed operant behavior all rely on conditions that support high and stable rates of the baseline behavior. To assess antinociception, these high baseline rates of behavior are depressed or punished by a pain stimulus, and candidate analgesics are evaluated for their effectiveness to block effects of the pain stimulus and restore behavioral rates to baseline levels. A measure of drug safety can be determined in these same procedures by evaluating drug effects on the same behavior in the absence of the pain stimulus. Virtually all drugs will impair behavior at high enough doses due to undesirable effects that could include sedation, convulsions, or paralysis. Thus, these procedures provide the framework for directly comparing drug potency and effectiveness to produce antinociception (drug effects on the target behavior in the presence of the pain stimulus) with potency and effectiveness to produce a general measure of behavioral toxicity (drug effects on the same behavior in the absence of the pain stimulus). High-priority drugs for further consideration would be those that have higher potency to alleviate pain-related depression of the target behavior than to produce behavioral toxicity as indicated by impairment of that behavior in the absence of the pain stimulus. For example, in the nesting procedure in mice shown in [Fig. 2](#F2){ref-type="fig"}, morphine was 7.5-fold more potent to block intraperitoneal acid-induced depression of nesting (ED~50~ = 0.72 mg/kg) than to decrease control nesting in the absence of the acid noxious stimulus (ED~50~ = 5.37 mg/kg) ([@B183]). This type of ratio can be calculated and compared across drugs to provide one measure of drug safety.

Place-conditioning, ICSS, and drug self-administration procedures can also be used to evaluate abuse potential as one type of undesirable effect especially relevant to the quest for alternatives to opioid analgesics. In place-conditioning procedures, abuse potential is indicated if drug administration in the absence of a pain stimulus produces a conditioned place preference ([@B261]). In ICSS procedures, abuse potential is indicated if drug administration in the absence of a pain stimulus increases ICSS rates ([@B181]). In drug self-administration, abuse potential is indicated if some dose of drug maintains higher rates of self-administration than drug vehicle ([@B34]; [@B193]). Thus, in all three types of procedure, drug effects in the presence of a pain stimulus can provide evidence of antinociception, whereas drug effects in the absence of the pain stimulus can provide evidence of abuse potential.

C. Mechanisms of Pain and Analgesia {#s29}
-----------------------------------

Procedures used to evaluate effects of candidate analgesics are also used to investigate underlying mechanisms of pain behaviors and identify new receptor targets for drug development. Research studies with novel pain behaviors described in this review are already shedding new light on mechanisms that may contribute to pain in humans and serve as druggable targets in analgesic drug development. For example, studies using ICSS and place-conditioning procedures have converged in highlighting a role for the mesolimbic dopamine system in the expression and treatment of pain. As noted in section II.C.4, the mesolimbic dopamine system consists of dopaminergic neurons that project from the ventral tegmental area to the nucleus accumbens, and this system plays a key role in mood and motivated behavior ([@B159]; [@B187]; [@B95]). Operant ICSS behavior can be maintained by electrical stimulation of excitatory inputs to the mesolimbic dopamine system, and as a result, the finding that pain stimuli such as intraperitoneal acid can depress ICSS suggested that pain stimuli might also depress activity of the mesolimbic dopamine system ([@B208]). Subsequent studies used in vivo microdialysis to confirm that intraperitoneal acid reduced dopamine release in the nucleus accumbens, and that analgesic drugs selectively blocked intraperitoneal acid-induced depression of both behavior and nucleus accumbens dopamine release ([@B128]; [@B156]). This evidence to suggest that pain states can depress mesolimbic dopamine activity is complemented by additional evidence to suggest that pain relief reciprocally stimulates mesolimbic dopamine activity ([@B287]; [@B277]). For example, in mice treated with either a paw-incision model of postsurgical inflammatory pain or a spinal nerve ligation model of neuropathic pain, commonly used clinical analgesics were effective to produce both a conditioned place preference and an increase in nucleus accumbens dopamine release without altering either of these measures in the absence of the pain stimuli ([@B287]). These preclinical findings agree with clinical evidence for a role of dopamine dysfunction in pain ([@B27]; [@B285]; [@B140]). Additionally, an implication of these findings is that existing or candidate antidepressant drugs such as bupropion or amitifadine, which block dopamine as well as serotonin and/or norepinephrine transporters to increase synaptic levels of these neurotransmitters, might warrant further consideration as treatments for the depressant effects of pain ([@B230]; [@B223]; [@B128]; [@B156]; [@B10]).

V. Conclusions {#s30}
==============

A consistent theme throughout this review has been the emphasis on strategies to improve preclinical-to-clinical translation of research with candidate analgesic drugs. In conclusion, four specific recommendations are offered to support this goal. First, translational research for analgesic drug development, as for any type of drug development, will benefit from alignment of outcome measures in animals and humans ([@B290]). This review has identified a taxonomy of pain-related unconditioned, classically conditioned, and operant conditioned behaviors that applies to both animals and humans, and translational fidelity is likely to be greatest when using a preclinical procedure to predict drug effects on that same type of behavior in humans ([@B179]). For example, if one is interested in predicting potential for a candidate analgesic to relieve pain-related behavioral depression and functional impairment in humans (as recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; [@B56]), then translational research would be best served by preclinical studies to examine effects of that drug on pain-related depression/punishment of unconditioned or operant behavior. Unfortunately, preclinical and clinical research are now badly misaligned. Specifically, the most widely used endpoints in preclinical studies measure withdrawal responses of one sort or another (i.e., pain-stimulated unconditioned behaviors), whereas the most widely used endpoints in human studies use verbal reports (i.e., a type of operant behavior in which the pain stimulus serves as a discriminative stimulus). This misalignment of behavioral endpoints has likely contributed to the poor record of preclinical-to-clinical translation of results with many candidate analgesics.

Second, this review has described the "antinociception matrix" as a tool to map results from preclinical drug testing onto an experimental space with coordinates defined by the range of possible pain stimuli and pain behaviors. Additionally, a novel path has been proposed for initial data collection within this experimental space. Current practices emphasize a "vertical" path that varies the pain stimulus while relying on a single category of pain behavior (pain-stimulated unconditioned behaviors). Pursuit of this path has been strikingly inefficient in generating effective analgesics for use in humans, and instead, it has generated a high number of false positives that appear promising based on preclinical results but then fail in clinical studies. Centrally acting *κ* opioid receptor agonists exemplify this type of failed translation. The alternative path recommended here emphasizes a "horizontal" path that evaluates multiple pain behaviors produced by a pain stimulus of interest. This path is proposed to be advantageous because it includes pain behaviors (e.g., pain-depressed behaviors) of particular clinical relevance, and because procedures that use different pain behaviors (e.g., pain-stimulated and pain-depressed unconditioned behaviors) can have complementary strengths and weaknesses that mutually compensate for each other. Coordinated use of these complementary procedures can be more effective than either type of procedure alone in prioritizing compounds for advancement to clinical studies. Drug effects on some of these behaviors in the absence of the pain stimulus can also provide useful information on drug safety to complement data on drug effectiveness.

Third, the progress of preclinical research should build not only on our successes but also on our failures. Inclusion of a positive control (e.g., an opioid or NSAID analgesic) is a common component of experimental design in studies with candidate analgesics and permits direct comparison of effects produced by a test drug with effects of a known analgesic. The recommendation here is to also include a pharmacologically active negative control from among the many candidates that have advanced to clinical testing and failed. For example, many of the studies summarized in this review used centrally acting *κ* opioid receptor agonists as negative controls. This class of drugs is useful as a source of negative controls because *κ* agonists have been extensively evaluated for decades in a wide range of different preclinical procedures, they produce analgesic-like effects in nearly all procedures using pain-stimulated unconditioned behaviors, but no *κ* agonists are approved to treat any type of pain anywhere in the world. Many other types of drug could also be used as a negative control ([@B289]), but regardless of the particular drug used, the inclusion of negative as well as positive controls has the value of clarifying dimensions of assay sensitivity and selectivity while providing within-study comparators for use in interpreting effects of candidate analgesics.

The final recommendation focuses not on the conduct of preclinical testing, but on our vocabulary for describing it. Specifically, the labeling of preclinical procedures would benefit from more precise terminology to specify both the putative pain stimulus (the independent variable) and the measured pain behavior (the dependent variable). For example, two procedures commonly used in preclinical research are often labeled as the "hot-plate" and "tail-flick" tests. In the first case, the label names the stimulus but not the behavior. In the second case, the label names the behavior but not the stimulus. More precise labels would name both the stimulus and the behavior using terminology such as "hot-plate paw-withdrawal" and "radiant-heat tail-flick" tests. The importance of this precision is already largely appreciated with regard to the independent "pain-stimulus" variable, and many investigators already use a language that identifies the modality of the stimulus (thermal, mechanical, chemical) and the presence or absence of inflammatory or neuropathic states. However, labeling often omits the name of the behavioral outcome measure, even though this is known to be a determinant of drug effects. Although it is admittedly more cumbersome, disciplined use of such terminology to clarify the behavioral endpoint would emphasize for the investigator and the audience both 1) the specific behavior being measured and 2) the process of inference that is necessarily involved in relating that behavior in animals to the experience of pain in humans. In a corollary to this point, it would be valuable not only to encourage the use of more precise labels for outcome measures but also to discourage (or at least qualify) the use of imprecise labels. In particular, it needs to be emphasized again that terms such as pain, analgesia, allodynia, and hyperalgesia describe patterns of verbal behavior in humans, but verbal behavior is not available as a source of outcome measures in preclinical research with animals. Use of these terms to describe vastly different behaviors in animals invites misunderstanding, complicates translation, and hinders thoughtful consideration of differences in the expression, mechanisms, and pharmacological modulation of the targeted behaviors.

This work was supported by the National Institutes of Health National Institute on Drug Abuse \[Grant R01-DA030404\] and the National Institutes of Health National Institute of Neurological Disorders and Stroke \[Grant R01-NS070715\].

<https://doi.org/10.1124/pr.118.017210>.

^1^In the study by [@B253], morphine did not produce differential CPP in rats with versus without the pain manipulation (intraplantar CFA) as assessed by a conventional measure of time spent in the drug-paired compartment. It did, however, produce selective CPP in intraplantar CFA rats by a different measure involving choice of the drug-paired compartment during repeated discrete-trial choice opportunities. This discrete-trial method of evaluating place preference was recommended by the author for use in place-conditioning studies of antinociception, but surprisingly, this approach was not used in a more recent study by this author ([@B224]), nor has it been adopted by others. Moreover, indomethacin failed to produce CPP in intraplantar CFA rats by either measure ([@B253]).
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